Acadia Healthcare (ACHC) 10-Q 5 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 05, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Trading Symbol	ACHC
Entity Registrant Name	Acadia Healthcare Company, Inc.
Entity Central Index Key	0001520697
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $.01 par value
Security Exchange Name	NASDAQ
Entity File Number	001-35331
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2492228
Entity Address, Address Line One	6100 Tower Circle
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	861-6000
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		88,963,135

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 211,939	$ 124,192
Accounts receivable, net	325,507	339,775
Other current assets	73,495	78,244
Total current assets	610,941	542,211
Property and equipment, net	3,160,784	3,224,034
Goodwill	2,425,372	2,449,131
Intangible assets, net	89,047	90,357
Deferred tax assets	3,274	3,339
Operating lease right-of-use assets	475,262	501,837
Other assets	68,548	68,233
Total assets	6,833,228	6,879,142
Current liabilities:
Current portion of long-term debt	48,465	43,679
Accounts payable	118,799	127,045
Accrued salaries and benefits	119,939	122,552
Current portion of operating lease liabilities	30,038	29,140
Other accrued liabilities	210,123	141,160
Total current liabilities	527,364	463,576
Long-term debt	3,078,445	3,105,420
Deferred tax liabilities	90,688	71,860
Operating lease liabilities	474,218	502,252
Derivative instrument liabilities	8,683	68,915
Other liabilities	116,553	128,587
Total liabilities	4,295,951	4,340,610
Redeemable noncontrolling interests	33,939	33,151
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 shares authorized; 87,897,964 and 87,715,591 issued and outstanding at June 30, 2020 and December 31, 2019, respectively	879	877
Additional paid-in capital	2,567,050	2,557,642
Accumulated other comprehensive loss	(500,879)	(414,884)
Retained earnings	436,288	361,746
Total equity	2,503,338	2,505,381
Total liabilities and equity	$ 6,833,228	$ 6,879,142

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	87,897,964	87,715,591
Common stock, shares outstanding	87,897,964	87,715,591

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue	$ 750,311	$ 789,362	$ 1,533,121	$ 1,549,979
Salaries, wages and benefits (including equity-based compensation expense of $5,808, $4,182, $10,787 and $10,283, respectively)	427,603	430,219	867,919	859,798
Professional fees	58,614	58,429	121,914	115,436
Supplies	30,124	30,914	62,095	60,871
Rents and leases	20,827	20,419	41,651	40,726
Other operating expenses	92,600	94,677	191,129	188,542
Other income	(18,070)		(18,070)
Depreciation and amortization	41,445	41,077	83,125	81,657
Interest expense, net	38,726	48,610	81,511	96,740
Debt extinguishment costs	3,271		3,271
Transaction-related expenses	5,241	5,212	8,790	9,533
Total expenses	700,381	729,557	1,443,335	1,453,303
Income before income taxes	49,930	59,805	89,786	96,676
Provision for income taxes	8,216	11,604	14,005	18,964
Net income	41,714	48,201	75,781	77,712
Net income attributable to noncontrolling interests	(635)	(61)	(1,239)	(101)
Net income attributable to Acadia Healthcare Company, Inc.	$ 41,079	$ 48,140	$ 74,542	$ 77,611
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ 0.47	$ 0.55	$ 0.85	$ 0.89
Diluted	$ 0.46	$ 0.55	$ 0.84	$ 0.88
Weighted-average shares outstanding:
Basic	87,872	87,618	87,818	87,562
Diluted	88,608	87,837	88,228	87,770

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Income (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Equity-based compensation expense	$ 5,808	$ 4,182	$ 10,787	$ 10,283

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 41,714	$ 48,201	$ 75,781	$ 77,712
Other comprehensive (loss) income:
Foreign currency translation loss	(7,183)	(50,618)	(129,183)	(6,137)
(Loss) gain on derivative instruments, net of tax of $(0.2) million, $9.2 million, $16.0 million and $5.7 million, respectively	(558)	17,587	43,188	8,897
Other comprehensive (loss) income	(7,741)	(33,031)	(85,995)	2,760
Comprehensive income (loss)	33,973	15,170	(10,214)	80,472
Comprehensive income attributable to noncontrolling interests	(635)	(61)	(1,239)	(101)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$ 33,338	$ 15,109	$ (11,453)	$ 80,371

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Gain (loss) on derivative instruments, tax	$ (0.2)	$ 9.2	$ 16	$ 5.7

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Earnings (Accumulated Deficit) [Member]
Balance at Dec. 31, 2018	$ 2,333,307	$ 874	$ 2,541,987	$ (462,377)	$ 252,823
Balance, shares at Dec. 31, 2018		87,444,000
Common stock issued under stock incentive plans	293	$ 2	291
Common stock issued under stock incentive plans, shares		149,000
Common stock withheld for minimum statutory taxes	(1,620)		(1,620)
Equity-based compensation expense	6,101		6,101
Other comprehensive income (loss)	35,791			35,791
Net income (loss) attributable to Acadia Healthcare Company, Inc.	29,471				29,471
Balance at Mar. 31, 2019	2,403,343	$ 876	2,546,759	(426,586)	282,294
Balance, shares at Mar. 31, 2019		87,593,000
Balance at Dec. 31, 2018	2,333,307	$ 874	2,541,987	(462,377)	252,823
Balance, shares at Dec. 31, 2018		87,444,000
Other comprehensive income (loss)	2,760
Net income (loss) attributable to Acadia Healthcare Company, Inc.	77,611
Balance at Jun. 30, 2019	2,422,346	$ 876	2,550,653	(459,617)	330,434
Balance, shares at Jun. 30, 2019		87,645,000
Balance at Dec. 31, 2018	$ 2,333,307	$ 874	2,541,987	(462,377)	252,823
Balance, shares at Dec. 31, 2018		87,444,000
Common stock issued under stock incentive plans, shares	55,671
Balance at Dec. 31, 2019	$ 2,505,381	$ 877	2,557,642	(414,884)	361,746
Balance, shares at Dec. 31, 2019	87,715,591	87,715,000
Balance at Mar. 31, 2019	$ 2,403,343	$ 876	2,546,759	(426,586)	282,294
Balance, shares at Mar. 31, 2019		87,593,000
Common stock issued under stock incentive plans	68		68
Common stock issued under stock incentive plans, shares		52,000
Common stock withheld for minimum statutory taxes	(356)		(356)
Equity-based compensation expense	4,182		4,182
Other comprehensive income (loss)	(33,031)			(33,031)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	48,140				48,140
Balance at Jun. 30, 2019	2,422,346	$ 876	2,550,653	(459,617)	330,434
Balance, shares at Jun. 30, 2019		87,645,000
Common stock issued under stock incentive plans	154	$ 1	153
Common stock issued under stock incentive plans, shares		10,000
Common stock withheld for minimum statutory taxes	(37)		(37)
Equity-based compensation expense	4,039		4,039
Other comprehensive income (loss)	(48,377)			(48,377)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	42,566				42,566
Balance at Sep. 30, 2019	2,420,691	$ 877	2,554,808	(507,994)	373,000
Balance, shares at Sep. 30, 2019		87,655,000
Common stock issued under stock incentive plans	54		54
Common stock issued under stock incentive plans, shares		60,000
Common stock withheld for minimum statutory taxes	(205)		(205)
Equity-based compensation expense	2,985		2,985
Other comprehensive income (loss)	93,110			93,110
Net income (loss) attributable to Acadia Healthcare Company, Inc.	(11,254)				(11,254)
Balance at Dec. 31, 2019	$ 2,505,381	$ 877	2,557,642	(414,884)	361,746
Balance, shares at Dec. 31, 2019	87,715,591	87,715,000
Common stock issued under stock incentive plans		$ 1	(1)
Common stock issued under stock incentive plans, shares		127,000
Common stock withheld for minimum statutory taxes	$ (1,402)		(1,402)
Equity-based compensation expense	4,979		4,979
Other comprehensive income (loss)	(78,254)			(78,254)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	33,463				33,463
Balance at Mar. 31, 2020	2,464,167	$ 878	2,561,218	(493,138)	395,209
Balance, shares at Mar. 31, 2020		87,842
Balance at Dec. 31, 2019	$ 2,505,381	$ 877	2,557,642	(414,884)	361,746
Balance, shares at Dec. 31, 2019	87,715,591	87,715,000
Common stock issued under stock incentive plans, shares	6,000
Other comprehensive income (loss)	$ (85,995)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	74,542
Balance at Jun. 30, 2020	$ 2,503,338	$ 879	2,567,050	(500,879)	436,288
Balance, shares at Jun. 30, 2020	87,897,964	87,898
Balance at Mar. 31, 2020	$ 2,464,167	$ 878	2,561,218	(493,138)	395,209
Balance, shares at Mar. 31, 2020		87,842
Common stock issued under stock incentive plans	170	$ 1	169
Common stock issued under stock incentive plans, shares		56,000
Common stock withheld for minimum statutory taxes	(145)		(145)
Equity-based compensation expense	5,808		5,808
Other comprehensive income (loss)	(7,741)			(7,741)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	41,079				41,079
Balance at Jun. 30, 2020	$ 2,503,338	$ 879	$ 2,567,050	$ (500,879)	$ 436,288
Balance, shares at Jun. 30, 2020	87,897,964	87,898

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities:
Net income	$ 75,781	$ 77,712
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	83,125	81,657
Amortization of debt issuance costs	6,382	5,887
Equity-based compensation expense	10,787	10,283
Deferred income taxes	22,045	(205)
Debt extinguishment costs	3,271
Other	(1,152)	2,395
Change in operating assets and liabilities:
Accounts receivable, net	11,066	(27,669)
Other current assets	(8,238)	(10,591)
Other assets	2,823	661
Accounts payable and other accrued liabilities	40,923	(11,060)
Accrued salaries and benefits	(794)	(3,232)
Other liabilities	18,925	2,848
Net cash provided by operating activities	264,944	128,686
Investing activities:
Cash paid for acquisitions, net of cash acquired		(44,900)
Cash paid for capital expenditures	(132,080)	(139,128)
Cash paid for real estate acquisitions	(4,415)	(4,448)
Proceeds from sale of property and equipment	1,412	11,649
Other	(4,849)	(1,155)
Net cash used in investing activities	(139,932)	(177,982)
Financing activities:
Borrowings on long-term debt	450,000
Borrowings on revolving credit facility	100,000	76,573
Principal payments on revolving credit facility	(100,000)	(11,573)
Principal payments on long-term debt	(21,242)	(16,492)
Repayment of long-term debt	(450,000)
Payment of debt issuance costs	(10,595)
Common stock withheld for minimum statutory taxes, net	(1,377)	(1,615)
Distributions to noncontrolling interests	(451)
Other	(2,344)	(4,345)
Net cash (used in) provided by financing activities	(36,009)	42,548
Effect of exchange rate changes on cash	(1,256)	(221)
Net increase (decrease) in cash and cash equivalents	87,747	(6,969)
Cash and cash equivalents at beginning of the period	124,192	50,510
Cash and cash equivalents at end of the period	$ 211,939	43,541
Effect of acquisitions:
Assets acquired, excluding cash		48,555
Liabilities assumed		(3,655)
Cash paid for acquisitions, net of cash acquired		$ 44,900

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Description of Business Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States (“U.S.”), the United Kingdom (“U.K.”) and Puerto Rico. At June 30, 2020, the Company operated 589 behavioral healthcare facilities with approximately 18,200 beds in 40 states, the U.K. and Puerto Rico. During 2019, the Company commenced a review of strategic alternatives including those related to its U.K. operations and a potential sale of such operations. In January 2020, the Company launched a formal process regarding the sale of its U.K. business. Consistent with market practice for U.K. transactions of this nature, and in conjunction with its advisors, the Company solicited and received initial, non-binding offers to acquire its U.K. business from multiple bidders. During the first quarter of 2020, the Company began the second phase of the sale process, during which interested bidders would receive proposed transaction documents and complete their confirmatory due diligence. However, given evolving market dynamics related to the novel coronavirus (“COVID-19”) pandemic, the Company suspended the sale process in mid-March 2020. While the interest from potential buyers has been strong, the sale process remains temporarily suspended. Basis of Presentation The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of our financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2020. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. During March 2020, the global pandemic of COVID-19 began to affect the Company’s facilities, employees, patients, communities, business operations and financial performance, as well as the broader U.S. and U.K. economies and financial markets. At a limited number of facilities, employees and/or patients have tested positive for COVID-19. The Company is committed to protecting the health of our communities and has been responding to the evolving COVID-19 situation while taking steps to provide quality care and protect the health and safety of patients and employees. All of the Company’s facilities are closely following infectious disease protocols, as well as recommendations by the Centers for Disease Control and Prevention (“CDC”), the National Health Service (“NHS”) and local health officials. The Company has established an internal COVID-19 taskforce, taken steps to secure its supply chain, expanded telehealth capabilities and implemented emergency planning in directly impacted markets. Nevertheless, COVID-19 is adversely impacting the Company’s business and will likely have an impact on its financial results that the Company is not currently able to quantify. Continuing disruptions to the Company’s business as a result of the COVID-19 pandemic could have a material adverse effect on its results of operations, financial condition, cash flows and ability to service its indebtedness and may affect the amounts reported in the consolidated financial statements including those related to collectability of accounts receivable as well as professional and general liability reserves, tax assets and liabilities and may result in a potential impairment of goodwill and long-lived assets. Certain reclassifications have been made to prior years to conform to the current year presentation.

Recently Issued Accounting Stan

Recently Issued Accounting Standards	6 Months Ended
	Jun. 30, 2020
Accounting Changes And Error Corrections [Abstract]
Recently Issued Accounting Standards	2. Recently Issued Accounting Standards In March 2020, the SEC adopted final rules that amend Rule 3-10 and Rule 3-16 of Regulation S-X to reduce and simplify the financial disclosure requirements applicable to guarantors and issuers of guaranteed securities, as well as for affiliates whose securities collateralize a registrant’s securities. The new rules are effective January 4, 2021. Early adoption is permitted. The Company early adopted the new rules during the three months ended June 30, 2020. In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting In August 2018, the FASB issued ASU 2018-15, “ Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In June 2016, the FASB issued ASU 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments .

The CARES Act

The CARES Act	6 Months Ended
	Jun. 30, 2020
Extraordinary And Unusual Items [Abstract]
The CARES Act	3. The CARES Act As part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), the U.S. government announced it would offer $100 billion of relief to eligible healthcare providers. On April 24, 2020, President Trump signed into law the Paycheck Protection Program and Health Care Enhancement Act (the “New PPP Act”). Among other things, the New PPP Act allocates $75 billion to eligible healthcare providers to help offset COVID-19 related losses and expenses. The $75 billion allocated under the New PPP Act is in addition to the $100 billion allocated to healthcare providers for the same purposes in the CARES Act and has been disbursed to providers under terms and conditions similar to the CARES Act funds. During the three months ended June 30, 2020, the Company participated in certain relief programs offered through the CARES Act, including receipt of approximately $20 million relating to the initial portions of the Public Health and Social Services Emergency Fund (“PHSSE Fund”) and approximately $45 million of payments from the Centers for Medicare and Medicaid Services’ (“CMS”) Accelerated and Advance Payment Program. In addition, the Company received a 2% increase in facilities’ Medicare reimbursement rate as a result of the temporary suspension of Medicare sequestration from May 1, 2020, to December 31, 2020. The CARES Act also provides for certain federal income and other tax changes, including an increase in the interest expense tax deduction limitation, the deferral of the employer portion of Social Security payroll taxes, refundable payroll tax credits, net operating loss carryback periods, alternative minimum tax credit refunds and bonus depreciation of qualified improvement property. The federal income tax changes brought about by the CARES Act are complex and further guidance is expected. The Company continues to review and determine the extent to which the tax provisions of the CARES Act will affect the Company. During the three months ended June 30, 2020, the Company recorded $18.1 million of income related to funds received under the CARES Act within other income in the condensed consolidated statements of income. The Company continues to evaluate its compliance with the terms and conditions to, and the financial impact of, funds received under the CARES Act and other government relief programs.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue	4 . Revenue Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract. As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in Accounting Standards Codification (“ASC”) ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities. The Company disaggregates revenue from contracts with customers by service type and by payor within each of the Company’s segments. U.S. Facilities The Company’s facilities in the United States (the “U.S. Facilities”) and services provided by the U.S. Facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; residential treatment centers; and outpatient community-based facilities. Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists. Specialty treatment facilities . Specialty treatment facilities include residential recovery facilities, eating disorder facilities and comprehensive treatment centers. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care. Residential treatment centers . Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities. Outpatient community-based facilities . Outpatient community-based programs are designed to provide therapeutic treatment to children and adolescents who have a clinically-defined emotional, psychiatric or chemical dependency disorder while enabling the youth to remain at home and within their community. The table below presents total U.S. revenue attributed to each category (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Acute inpatient psychiatric facilities $ 224,844 $ 229,128 $ 464,258 $ 445,725 Specialty treatment facilities 192,479 201,269 386,090 394,304 Residential treatment centers 68,845 74,084 139,279 147,308 Outpatient community-based facilities 5,307 5,332 11,065 10,436 Revenue $ 491,475 $ 509,813 $ 1,000,692 $ 997,773 The Company receives payments from the following sources for services rendered in our U.S. Facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; and (iv) individual patients and clients. The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of our U.S. Facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the condensed cons olidated statements of income. Bad debt expense for the three and six months ended June 30, 2020 and 201 9 was not significant. The following table presents revenue by payor type and as a percentage of revenue in our U.S. Facilities (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Amount % Amount % Amount % Amount % Commercial $ 140,028 28.5 % $ 146,917 28.8 % $ 283,170 28.3 % $ 286,344 28.7 % Medicare 75,914 15.4 % 73,505 14.4 % 148,185 14.8 % 146,121 14.6 % Medicaid 245,690 50.0 % 255,070 50.0 % 505,734 50.5 % 494,261 49.5 % Self-Pay 22,476 4.6 % 29,624 5.8 % 49,510 5.0 % 61,356 6.2 % Other 7,367 1.5 % 4,697 1.0 % 14,093 1.4 % 9,691 1.0 % Revenue $ 491,475 100.0 % $ 509,813 100.0 % $ 1,000,692 100.0 % $ 997,773 100.0 % Contract liabilities in the U.S. Facilities primarily consisted of unearned revenues from CMS’ Accelerated and Advance Payment Program. Contract liabilities are included in other accrued liabilities on the condensed consolidated balance sheets. In April 2020, the Company received approximately $45 million from CMS’ Accelerated and Advance Payment Program for Medicare providers. The repayment of these accelerated/advance payments does not begin until 120 days after the date of issuance of payment. Once repayment is required, the amount will be recouped from the provider’s or supplier’s new Medicare claims. The facilities will generally have 210 days from the date of payment to repay the amounts that they owe. The Company expects the approximately $45 million received to be repaid over a three-month period from August to November 2020. A summary of the activity in unearned revenue in the U.S. Facilities is as follows (in thousands): Balance at December 31, 2019 $ 1,896 Payments received $ 49,332 Revenue recognized (3,366 ) Balance at June 30, 2020 $ 47,862 U.K. Facilities The Company’s facilities located in the United Kingdom (the “U.K. Facilities”) and services provided by the U.K. Facilities can generally be classified into the following categories: healthcare facilities; education and children’s services; and adult care facilities. Healthcare facilities . Healthcare facilities provide psychiatric treatment and nursing for sufferers of mental disorders, including for patients whose risk of harm to others and risk of escape from hospitals cannot be managed safely within other mental health settings. In order to manage the risks involved with treating patients, the facility is managed through the application of a range of security measures depending on the level of dependency and risk exhibited by the patient. Education and children’s services. Education and children’s services provide specialist education for children and young people with special educational needs, including autism, Asperger’s Syndrome, social, emotional and mental health, and specific learning difficulties, such as dyslexia. The division also offers standalone children’s homes for children that require 52-week residential care to support complex and challenging behavior and fostering services. Adult care facilities . Adult care focuses on care of individuals with a variety of learning difficulties, mental health illnesses and adult autism spectrum disorders. It also includes long-term, short-term and respite nursing care to high-dependency elderly individuals who are physically frail or suffering from dementia. Care is provided in a number of settings, including in residential care homes and through supported living. The table below presents total U.K. revenue attributed to each category (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Healthcare facilities $ 137,538 $ 155,553 $ 285,675 $ 307,261 Education and Children’s Services 44,630 46,142 91,296 92,264 Adult Care facilities 76,668 77,854 155,458 152,681 Revenue $ 258,836 $ 279,549 $ 532,429 $ 552,206 On an annual basis, the Company receives payments from approximately 500 public funded sources in the U.K. (including the NHS, Clinical Commissioning Groups (“CCGs”) and local authorities in England, Scotland and Wales) and individual patients and clients. The Company determines the transaction price based on established billing rates by payor reduced by implicit price concessions. Implicit price concessions are insignificant in the U.K. Facilities. The following table presents revenue by payor type and as a percentage of revenue in our U.K. Facilities (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Amount % Amount % Amount % Amount % U.K. public funded sources $ 235,685 91.1 % $ 252,332 90.3 % $ 481,821 90.5 % $ 497,745 90.1 % Self-Pay 22,556 8.7 % 26,651 9.5 % 49,471 9.3 % 53,465 9.7 % Other 595 0.2 % 566 0.2 % 1,137 0.2 % 996 0.2 % Revenue $ 258,836 100.0 % $ 279,549 100.0 % $ 532,429 100.0 % $ 552,206 100.0 % Contract liabilities in the U.K. Facilities primarily consist of unearned revenue due to the timing of payments received mainly in our education and children’s services and healthcare facilities. Contract liabilities are included in other accrued liabilities on the condensed consolidated balance sheets. A summary of the activity in unearned revenue in the U.K. Facilities is as follows (in thousands): Balance at December 31, 2019 $ 36,579 Payments received 76,680 Revenue recognized (83,748 ) Foreign currency translation loss (1,947 ) Balance at June 30, 2020 $ 27,564

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share	5 . The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2020 and 2019 (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Numerator: Net income attributable to Acadia Healthcare Company, Inc. $ 41,079 $ 48,140 $ 74,542 $ 77,611 Denominator: Weighted average shares outstanding for basic earnings per share 87,872 87,618 87,818 87,562 Effect of dilutive instruments 736 219 410 208 Shares used in computing diluted earnings per common share 88,608 87,837 88,228 87,770 Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders: Basic $ 0.47 $ 0.55 $ 0.85 $ 0.89 Diluted $ 0.46 $ 0.55 $ 0.84 $ 0.88 Approximately 2.4 million and 1.9 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the three months ended June 30, 2020 and 2019, respectively, because their effect would have been anti-dilutive. Approximately 2.2 million and 2.4 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for both the six months ended June 30, 2020 and 2019, respectively, because their effect would have been anti-dilutive.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Acquisitions	6 . The Company’s strategy is to acquire and develop behavioral healthcare facilities and improve operating results within its facilities and its other behavioral healthcare operations. On April 1, 2019, the Company completed the acquisition of Bradford Recovery Center (“Bradford”), a specialty treatment facility with 46 beds located in Millerton, Pennsylvania, for cash consideration of approximately $4.5 million. On February 15, 2019, the Company completed the acquisition of Whittier Pavilion (“Whittier”), an inpatient psychiatric facility with 71 beds located in Haverhill, Massachusetts, for cash consideration of approximately $17.9 million. Also on February 15, 2019, the Company completed the acquisition of Mission Treatment (“Mission Treatment”) for cash consideration of approximately $22.5 million. Mission Treatment operates nine comprehensive treatment centers in California, Nevada, Arizona and Oklahoma. Transaction-related expenses Transaction-related expenses primarily relate to termination, restructuring, U.K. sale, strategic review, management transition and other similar costs. Transaction-related expenses for the three and six months ended June 30, 2020 and 2019 were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Legal, accounting and other acquisition-related costs $ 5,202 $ 420 $ 6,530 $ 1,216 Termination, restructuring, sale and strategic review costs 39 3,330 2,260 5,612 Management transition costs — 1,462 — 2,705 $ 5,241 $ 5,212 $ 8,790 $ 9,533

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Property and Equipment	7 . Property and Equipment Property and equipment consisted of the following at June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Land $ 430,222 $ 448,716 Building and improvements 2,747,858 2,746,111 Equipment 503,569 516,769 Construction in progress 257,707 254,213 3,939,356 3,965,809 Less: accumulated depreciation (778,572 ) (741,775 ) Property and equipment, net $ 3,160,784 $ 3,224,034 The Company has recorded assets held for sale within other assets on the condensed consolidated balance sheets for closed properties being actively marketed of $28.6 million and $31.1 million at June 30, 2020 and December 31, 2019, respectively.

Other Intangible Assets

Other Intangible Assets	6 Months Ended
	Jun. 30, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Other Intangible Assets	8 . Other Intangible Assets Other identifiable intangible assets and related accumulated amortization consisted of the following at June 30, 2020 and December 31, 2019 (in thousands): Gross Carrying Amount Accumulated Amortization June 30, 2020 December 31, 2019 June 30, 2020 December 31, 2019 Intangible assets subject to amortization: Contract intangible assets $ 2,100 $ 2,100 $ (2,100 ) $ (2,100 ) Non-compete agreements 1,131 1,131 (1,131 ) (1,131 ) 3,231 3,231 (3,231 ) (3,231 ) Intangible assets not subject to amortization: Licenses and accreditations 12,427 12,455 — — Trade names 59,457 60,831 — — Certificates of need 17,163 17,071 — — 89,047 90,357 — — Total $ 92,278 $ 93,588 $ (3,231 ) $ (3,231 ) All of the Company’s definite-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	9. The Company’s lease portfolio primarily consists of finance and operating real estate leases integral for facility operations. The original terms of the leases typically range from five to 30 years with optional renewal periods. A minimal portion of the Company’s lease portfolio consists of non-real estate leases, including copiers and equipment, which generally have lease terms of one to three years and have insignificant lease obligations. The Company has elected the accounting policy practical expedients by class of underlying asset in ASC 842 “Leases” to: (i) combine associated lease and non-lease components into a single lease component; and (ii) exclude recording short-term leases as right-of-use assets and liabilities on the condensed consolidated balance sheets. Non-lease components, which are not significant overall, are combined with lease components. Operating lease liabilities are recorded at the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for prepayments, accrued lease payments, lease incentives and initial direct costs. Certain of the Company’s leases include renewal or termination options. Calculation of operating lease right-of-use assets and liabilities include the initial lease term unless it is reasonably certain a renewal or termination option will be exercised. Variable components of lease payments fluctuating with a future index or rate, as well as those related to common area maintenance costs, are not included in determining lease payments and are expensed as incurred. Most of the Company’s leases do not contain implicit borrowing rates, and therefore, incremental borrowing rates are calculated based on information available at the lease commencement date. Incremental borrowing rates reflect the Company’s estimated interest rates for collateralized borrowings over similar lease terms. Additionally, the Company reviews service agreements for embedded lease and right-of-use assets and liabilities as necessary. Lease Position The Company recorded the following at June 30, 2020 and December 31, 2019 on the condensed consolidated balance sheets (in thousands): Right-of-Use Assets Balance Sheet Classification June 30, 2020 December 31, 2019 Finance lease right-of-use assets Property and equipment, net $ 43,119 $ 44,370 Operating lease right-of-use assets Operating lease right-of-use assets 475,262 501,837 Total $ 518,381 $ 546,207 Lease Liabilities Balance Sheet Classification June 30, 2020 December 31, 2019 Current: Finance lease liabilities Other accrued liabilities $ 35,229 $ 6,819 Operating lease liabilities Current portion of operating lease liabilities 30,038 29,140 Noncurrent: Finance lease liabilities Other liabilities 14,156 43,662 Operating lease liabilities Operating lease liabilities 474,218 502,252 Total $ 553,641 $ 581,873 Weighted-average remaining lease terms and discount rates were as follows at June 30, 2020 and December 31, 2019: June 30, 2020 December 31, 2019 Weighted-average remaining lease term (in years): Finance 6.6 6.9 Operating 18.8 19.4 Weighted-average discount rate: Finance 6.4 % 6.4 % Operating 6.3 % 6.3 % Lease Costs The Company recorded the following lease costs for the three and six months ended June 30, 2020 and 2019 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Finance lease costs: Depreciation of leased assets 1,048 1,136 2,185 2,259 Interest of lease liabilities 985 999 1,982 1,996 Total finance lease costs $ 2,033 $ 2,135 $ 4,167 $ 4,255 Operating lease costs 16,339 16,237 32,820 32,766 Variable lease costs 1,560 1,044 2,870 1,930 Short term lease costs 1,171 1,483 2,318 2,930 Other lease costs 1,757 1,655 3,643 3,100 Total rents and leases $ 20,827 $ 20,419 $ 41,651 $ 40,726 Total lease costs $ 22,860 $ 22,554 $ 45,818 $ 44,981 Other Undiscounted cash flows for finance and operating leases recorded on the condensed consolidated balance sheets were as follows at June 30, 2020 (in thousands): Finance Leases Operating Leases For the six months ending December 31, 2020 $ 3,690 $ 30,992 2021 35,839 59,215 2022 2,977 54,032 2023 1,768 49,413 2024 1,087 47,082 Thereafter 25,087 657,618 Total minimum lease payments 70,448 898,352 Less: amount of lease payments representing interest 21,063 394,096 Present value of future minimum lease payments 49,385 504,256 Less: Current portion of lease liabilities 35,229 30,038 Noncurrent lease liabilities $ 14,156 $ 474,218 Supplemental data for the three and six months ended June 30, 2020 and 2019 was as follows (in thousands): Six Months Ended June 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 31,596 $ 31,212 Operating cash flows for finance leases $ 1,982 $ 1,996 Financing cash flows for finance leases $ 1,768 $ 1,684 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 16,939 $ 10,674 Finance leases $ 1,462 $ 1,774

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Long-Term Debt	10. Long-Term Debt Long-term debt consisted of the following (in thousands): June 30, 2020 December 31, 2019 Amended and Restated Senior Credit Facility: Senior Secured Term A Loan $ 332,500 $ 346,750 Senior Secured Term B Loans 1,331,936 1,338,928 Senior Secured Revolving Line of Credit — — 6.125% Senior Notes due 2021 — 150,000 5.125% Senior Notes due 2022 — 300,000 5.625% Senior Notes due 2023 650,000 650,000 6.500% Senior Notes due 2024 390,000 390,000 5.500% Senior Notes due 2028 450,000 — Other long-term debt 4,235 4,821 Less: unamortized debt issuance costs, discount and premium (31,761 ) (31,400 ) 3,126,910 3,149,099 Less: current portion (48,465 ) (43,679 ) Long-term debt $ 3,078,445 $ 3,105,420 Amended and Restated Senior Credit Facility The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”). The Company has amended the Amended and Restated Credit Agreement from time to time as described in the Company’s prior filings with the SEC. On February 6, 2019, the Company entered into the Eleventh Amendment (the “Eleventh Amendment”) to the Amended and Restated Credit Agreement. The Eleventh Amendment, among other things, amended the definition of “Consolidated EBITDA” to remove the cap on non-cash charges, losses and expenses related to the impairment of goodwill, which in turn provided increased flexibility to the Company in terms of the Company’s financial covenants. On February 27, 2019, the Company entered into the Twelfth Amendment (the “Twelfth Amendment”) to the Amended and Restated Credit Agreement. The Twelfth Amendment, among other things, modified certain definitions, including “Consolidated EBITDA”, and increased our permitted Maximum Consolidated Leverage Ratio, thereby providing increased flexibility to the Company in terms of the Company’s financial covenants. On April 21, 2020, the Company entered into the Thirteenth Amendment (the “Thirteenth Amendment”) to the Amended and Restated Credit Agreement. The Thirteenth Amendment amended the Consolidated Leverage Ratio in the existing covenant to increase the leverage ratio for the rest of 2020. The Company had $485.6 million of availability under the revolving line of credit and had standby letters of credit outstanding of $14.4 million related to security for the payment of claims required by its workers’ compensation insurance program at June 30, 2020. In early April 2020, the Company borrowed $100.0 million on the revolving line of credit to enhance its cash position in response to the potential impact of COVID-19 on the Company’s future liquidity and subsequently repaid this amount in late May 2020. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our Term Loan A facility (“TLA Facility”) of $7.1 million for September 30, 2020 to December 31, 2020, and $9.5 million for March 31, 2021 to September 30, 2021, with the remaining principal balance of the TLA Facility due on the maturity date of November 30, 2021. The Company is required to repay the Term Loan B facility Tranche B-3 (the “Tranche B-3 Facility”) in equal quarterly installments of $1.2 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Tranche B-3 Facility of $447.3 million due on February 11, 2022. The Company is required to repay the Term Loan B facility Tranche B-4 (the “Tranche B-4 Facility”) in equal quarterly installments of approximately $2.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Tranche B-4 Facility of $854.4 million due on February 16, 2023. Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to the Company’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $50.0 million of unrestricted and unencumbered cash to consolidated EBITDA). The Applicable Rate for the Pro Rata Facilities was 2.50% for Eurodollar Rate Loans and 1.50% for Base Rate Loans at June 30, 2020. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (based upon the LIBOR Rate prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.00%. At June 30, 2020, the Pro Rata Facilities bore interest at a rate of LIBOR plus 2.50%. In addition, the Company is required to pay a commitment fee on undrawn amounts under the revolving line of credit. Borrowings with respect to the Tranche B-3 Facility bear interest as follows: Eurodollar Rate loans bear interest at the Tranche B-3 Facility Applicable Rate (as defined below) plus the Eurodollar Rate (based upon the LIBOR Rate prior to commencement of the interest rate period). Base Rate Loans bear interest at the Tranche B-3 Facility Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As used herein, the term “Tranche B-3 Facility Applicable Rate” means, with respect to Eurodollar Rate Loans, 2.50%, and with respect to Base Rate Loans, 1.50%. The Tranche B-4 Facility bears interest as follows: Eurodollar Rate Loans bear interest at the Tranche B-4 Facility Applicable Rate (as defined below) plus the Eurodollar Rate (based upon the LIBOR Rate prior to commencement of the interest rate period) and Base Rate Loans bear interest at the Tranche B-4 Facility Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As used herein, the term “Tranche B-4 Facility Applicable Rate” means, with respect to Eurodollar Rate Loans, 2.50 %, and with respect to Base Rate Loans, 1.50 %. At June 30, 2020 , the Tranche B-3 Facility and the Tranche B-4 Facility bore interest at a rate of LIBOR plus 2.50 %. The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. At June 30, 2020, the Company was in compliance with such covenants. Senior Notes 6.125% Senior Notes due 2021 On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. 5.125% Senior Notes due 2022 On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year. Redemption of 6.125% Senior Notes and 5.125% Senior Notes On June 10, 2020, the Company issued conditional notices of full redemption providing for the redemption in full of the 6.125% Senior Notes and 5.125% Senior Notes on July 10, 2020 (the “Redemption Date”), in each case at a redemption price equal to 100.0% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but not including the Redemption Date (the “Redemption Price”). On June 24, 2020, the Company satisfied and discharged the indentures governing the 6.125% Senior Notes and the 5.125% Senior Notes by irrevocably depositing with a trustee sufficient funds equal to the Redemption Price for the 6.125% Senior Notes and the 5.125% Senior Notes and otherwise complying with the terms in the indentures relating to the satisfaction and discharge of the 6.125% Senior Notes and the 5.125% Senior Notes. In connection with the redemption of the 6.125% Senior Notes and the 5.125% Senior Notes, the Company recorded a debt extinguishment charge of $3.3 million, including the write-off of the deferred financing and other costs in the condensed consolidated statements of income. 5.625% Senior Notes due 2023 On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company has outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year. 6.500% Senior Notes due 2024 On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016. 5.500% Senior Notes due 2028 On June 24, 2020, the Company issued $450.0 million of 5.500% Senior Notes due 2028 (the “5.500% Senior Notes”). The 5.500% Senior Notes mature on July 1, 2028 and bear interest at a rate of 5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021. The indentures governing the 5.625% Senior Notes, 6.500% Senior Notes and 5.500% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets. The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several. The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

Equity-Based Compensation

Equity-Based Compensation	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity-Based Compensation	1 1 . Equity-Based Compensation Equity Incentive Plans The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). At June 30, 2020, a maximum of 8,200,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 1,064,029 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the most recent closing price of the Company’s common stock on the most recent trading date prior to the date of grant. The Company recognized $5.8 million and $4.2 million in equity-based compensation expense for the three months ended June 30, 2020 and 2019, respectively and $10.8 million and $10.3 million for the six months ended June 30, 2020 and 2019, respectively. At June 30, 2020, there was $46.1 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.4 years. At June 30, 2020, there were no warrants outstanding and exercisable. The Company recognized a deferred income tax benefit of $1.5 million and $1.1 million for the three months ended June 30, 2020 and 2019, respectively, related to equity-based compensation expense. The Company recognized a deferred income tax benefit of $2.9 million and $2.8 million for the six months ended June 30, 2020 and 2019, respectively, related to equity-based compensation expense. Stock Options Stock option activity during 2019 and 2020 was as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Options outstanding at January 1, 2019 1,199,540 $ 44.64 7.26 $ 2,717 Options granted 605,200 28.50 9.21 1,343 Options exercised (55,671 ) 19.05 N/A 658 Options cancelled (389,001 ) 40.84 N/A N/A Options outstanding at December 31, 2019 1,360,068 39.40 7.57 1,650 Options granted 443,200 33.72 9.66 — Options exercised (6,000 ) 28.25 N/A 15 Options cancelled (160,462 ) 40.42 N/A N/A Options outstanding at June 30, 2020 1,636,806 $ 37.80 7.73 $ 361 Options exercisable at December 31, 2019 513,290 $ 48.08 5.88 $ 512 Options exercisable at June 30, 2020 690,781 $ 44.33 6.10 $ 361 Fair values are estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the six months ended June 30, 2020 and year ended December 31, 2019 : June 30, 2020 December 31, 2019 Weighted average grant-date fair value of options $ 12.29 $ 17.59 Risk-free interest rate 1.6 % 2.4 % Expected volatility 39 % 38 % Expected life (in years) 5.0 5.0 The Company’s estimate of expected volatility for stock options is based upon the volatility of our stock price over the expected life of the award. The risk-free interest rate is the approximate yield on U.S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised. Other Stock-Based Awards Restricted stock activity during 2019 and 2020 was as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2019 805,057 $ 42.40 Granted 700,937 28.77 Cancelled (389,684 ) 33.50 Vested (311,174 ) 44.23 Unvested at December 31, 2019 805,136 $ 34.14 Granted 557,269 25.27 Cancelled (82,608 ) 35.30 Vested (216,474 ) 37.24 Unvested at June 30, 2020 1,063,323 $ 28.77 Restricted stock unit activity during 2019 and 2020 was as follows: Number of Units Weighted Average Grant-Date Fair Value Unvested at January 1, 2019 484,111 $ 44.52 Granted 234,408 34.54 Cancelled (271,162 ) 45.17 Vested — — Unvested at December 31, 2019 447,357 $ 38.89 Granted 583,680 10.60 Cancelled (10,123 ) 42.09 Vested (12,691 ) 42.09 Unvested at June 30, 2020 1,008,223 $ 22.44 Restricted stock awards are time-based vesting awards that vest over a period of three or four years and are subject to continuing service of the employee or non-employee director over the ratable vesting periods. The fair values of the restricted stock awards were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date. Restricted stock units are granted to employees and are subject to Company performance compared to pre-established targets and Company performance compared to peers. In addition to Company performance, these performance-based restricted stock units are subject to the continuing service of the employee during the two- or three-year companies within the Healthcare Providers & Services 6 digit GICS industry group and selected other companies deemed to be peers. The number of shares issuable at the end of the applicable vesting period of restricted stock units ranges from 0 % to 200 % of the targeted units based on the Company’s actual performance compared to the targets and, for 2020 and 2019 awards, performance compared to peers. The fair values of restricted stock units were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at its Monte-Carlo simulation value for units subject to market conditions.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	1 2 . Income Taxes The provision for income taxes for the three months ended June 30, 2020 and 2019 reflects effective tax rates of 16.5% and 19.4%, respectively, while the provision for income taxes for the six months ended June 30, 2020 and 2019 reflects effective tax rates of 15.6% and 19.6%, respectively. The decrease in the effective tax rates for the current year is primarily attributable to changes in the Company’s valuation allowance related to a decrease in the deferred tax asset on carried forward interest that is deductible as a result of the CARES Act interest deductibility changes. As we continue to monitor tax implications of the CARES Act and other state, federal and foreign stimulus and tax legislation, we may make adjustments to our estimates and record additional amounts for tax assets and liabilities. Additionally, market disruption due to COVID-19 may affect the Company’s ability to realize our deferred tax assets. Any adjustments to our tax assets and liabilities could materially impact our provision for income taxes and our effective tax rate in the periods in which they are made.

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2020
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivatives	13 . Derivatives The Company periodically enters into foreign currency forward contracts in connection with certain transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. Foreign currency forward contracts limit the economic risk of changes in the exchange rate between U.S. Dollars (“USD”) and British Pounds (“GBP”) associated with cash transfers. In May 2016, the Company entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereafter, to fixed-rate GBP-denominated debt of £449.3 million. In August 2019, the Company terminated its existing net investment cross currency swap derivatives of $105.0 million. Cash received from the termination of the cross currency swap derivatives was included in investing activities in the condensed consolidated statement of cash flows. The related gain from this termination was included in accumulated other comprehensive loss in accordance with ASC 815-30-40-1. In August 2019, the Company also entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate GBP-denominated debt of £538.1 million. During the term of the swap agreements, the Company will receive semi-annual interest payments in USD from the counterparties at fixed interest rates, and the Company will make semi-annual interest payments in GBP to the counterparties at fixed interest rates. The interest payments under the cross-currency swap agreements result in £25.4 million of annual cash flows from the Company’s U.K. business being converted to $35.8 million. The Company has designated the cross currency swap agreements and forward contracts entered into during 2019 and the six months ended June 30, 2020 as qualifying hedging instruments and is accounting for these derivatives as net investment hedges. The fair values of these derivatives at June 30, 2020 and December 31, 2019 of $(8.7) million and $(68.9) million, respectively, are recorded as derivative instrument liabilities in the condensed consolidated balance sheets. During 2019, the Company elected the spot method for recording its net investment hedges. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense on the condensed consolidated statements of income. Gains and losses resulting from fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive loss as the swaps are effective in hedging the designated risk. Cash flows related to the cross currency swap derivatives are included in operating activities in the condensed consolidated statements of cash flows.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	14 . Fair Value Measurements The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments. The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 5.500% Senior Notes, other long-term debt and derivative instruments at June 30, 2020 and December 31, 2019 were as follows (in thousands): Carrying Amount Fair Value June 30, 2020 December 31, 2019 June 30, 2020 December 31, 2019 Amended and Restated Senior Credit Facility $ 1,649,288 $ 1,668,062 $ 1,649,288 $ 1,668,062 6.125% Senior Notes due 2021 $ — $ 149,254 $ — $ 149,441 5.125% Senior Notes due 2022 $ — $ 297,761 $ — $ 299,994 5.625% Senior Notes due 2023 $ 645,546 $ 644,771 $ 652,001 $ 655,249 6.500% Senior Notes due 2024 $ 385,023 $ 384,430 $ 385,023 $ 398,366 5.500% Senior Notes due 2028 $ 442,818 $ — $ 454,442 $ — Other long-term debt $ 4,235 $ 4,821 $ 4,235 $ 4,821 Derivative instrument liabilities $ (8,683 ) $ (68,915 ) $ (8,683 ) $ (68,915 ) The Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 5.500% Senior Notes and other long-term debt were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates. The fair values of the derivative instruments were categorized as Level 2 in the GAAP fair value hierarchy and were based on observable market inputs including applicable exchange rates and interest rates.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	15 . Commitments and Contingencies Professional and General Liability A portion of the Company’s professional liability risks are insured through a wholly-owned insurance subsidiary. The Company is self-insured for professional liability claims up to $3.0 million per claim and has obtained reinsurance coverage from a third party to cover claims in excess of the retention limit. The reinsurance policy has a coverage limit of $75.0 million in the aggregate. The Company’s reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place. Legal Proceedings The Company is, from time to time, subject to various claims, lawsuits, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Certain of the Company’s individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations, and violations of the False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the federal False Claims Act permits private parties to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled St. Clair County Employees’ Retirement System v. Acadia Healthcare Company, Inc., et al. and Rule 10b-5 promulgated thereunder. At this time, we are not able to quantify any potential liability in connection with this litigation because the case is in its early stages. On February 21, 2019, a purported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Davydov v. Joey A. Jacobs, et al. Beard v. Jacobs, et al. Davydov Beard St. Clair County v. Acadia Healthcare On April 25, 2018, plaintiff filed Pence v. Sober Living By the Sea, Inc Pence v. Sober Living by the Sea, Inc.; Acadia Healthcare Company, Inc. In the fall of 2017, the Office of Inspector General issued subpoenas to three of the Company’s facilities requesting certain documents from January 2013 to the date of the subpoenas. The U.S. Attorney’s Office for the Middle District of Florida issued a civil investigative demand to one of the Company’s facilities in December 2017 requesting certain documents from November 2012 to the date of the demand. In April 2019, the Office of Inspector General issued subpoenas relating to six additional facilities requesting certain documents and information from January 2013 to the date of the subpoenas. The government’s investigation of each of these facilities is focused on claims not eligible for payment because of alleged violations of certain regulatory requirements relating to, among other things, medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company is cooperating with the government’s investigation but is not able to quantify any potential liability in connection with these investigations.

Noncontrolling Interests

Noncontrolling Interests	6 Months Ended
	Jun. 30, 2020
Noncontrolling Interest [Abstract]
Noncontrolling Interests	1 6 . Noncontrolling Interests Noncontrolling interests in the consolidated financial statements represents the portion of equity held by noncontrolling partners in the Company’s non-wholly owned subsidiaries. At June 30, 2020, the Company operated five facilities through non-wholly owned subsidiaries. The Company owns between 60% and 86% of the equity interests of these entities and noncontrolling partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions, and the Company consolidates the operations of each facility based on its equity ownership and its control of the entity. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying condensed consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control. The components of redeemable noncontrolling interests are as follows (in thousands): Balance at December 31, 2019 $ 33,151 Net income attributable to noncontrolling interests 1,239 Dividend payments to noncontrolling interests (451 ) Balance at June 30, 2020 $ 33,939

Other Current Assets

Other Current Assets	6 Months Ended
	Jun. 30, 2020
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Other Current Assets	1 7 . Other Current Assets Other current assets consisted of the following (in thousands): June 30, 2020 December 31, 2019 Prepaid expenses $ 20,010 $ 23,708 Other receivables 13,970 16,097 Income taxes receivable 11,437 5,579 Workers’ compensation deposits – current portion 10,000 10,000 Cost report receivable 9,716 13,723 Inventory 4,712 4,759 Insurance receivable – current portion 1,844 3,030 Other 1,806 1,348 Other current assets $ 73,495 $ 78,244

Other Accrued Liabilities

Other Accrued Liabilities	6 Months Ended
	Jun. 30, 2020
Other Liabilities Disclosure [Abstract]
Other Accrued Liabilities	1 8 . Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands): June 30, 2020 December 31, 2019 Unearned revenue $ 75,426 $ 38,475 Accrued expenses 52,977 50,614 Finance lease liabilities 35,229 6,819 Accrued interest 23,228 33,323 Accrued property taxes 6,377 4,755 Income taxes payable 6,196 — Insurance liability – current portion 4,731 4,731 Other 5,959 2,443 Other accrued liabilities $ 210,123 $ 141,160

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Segment Information	1 9 . Segment Information The Company operates in one line of business, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its U.S. Facilities and its U.K. Facilities separately to assess performance and make decisions, the Company’s operating segments include our U.S. Facilities and U.K. Facilities. At June 30, 2020, the U.S. Facilities segment included 231 behavioral healthcare facilities with approximately 9,600 beds in 40 states and Puerto Rico, and the U.K. Facilities segment included 358 behavioral healthcare facilities with approximately 8,600 beds in the U.K. The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income before income taxes (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Revenue: U.S. Facilities $ 491,475 $ 509,813 $ 1,000,692 $ 997,773 U.K. Facilities 258,836 279,549 532,429 552,206 Corporate and Other — — — — $ 750,311 $ 789,362 $ 1,533,121 $ 1,549,979 Segment EBITDA (1): U.S. Facilities $ 134,881 $ 135,396 $ 254,955 $ 254,404 U.K. Facilities 31,639 45,835 67,807 85,891 Corporate and Other (22,099 ) (22,345 ) (45,492 ) (45,406 ) $ 144,421 $ 158,886 $ 277,270 $ 294,889 Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Segment EBITDA (1) $ 144,421 $ 158,886 $ 277,270 $ 294,889 Less: Equity-based compensation expense (5,808 ) (4,182 ) (10,787 ) (10,283 ) Transaction-related expenses (5,241 ) (5,212 ) (8,790 ) (9,533 ) Debt extinguishment costs (3,271 ) — (3,271 ) — Interest expense, net (38,726 ) (48,610 ) (81,511 ) (96,740 ) Depreciation and amortization (41,445 ) (41,077 ) (83,125 ) (81,657 ) Income before income taxes $ 49,930 $ 59,805 $ 89,786 $ 96,676 U.S. Facilities U.K. Facilities Corporate and Other Consolidated Goodwill: Balance at January 1, 2020 Goodwill $ 2,085,104 $ 689,902 $ — $ 2,775,006 Accumulated impairment loss — (325,875 ) — (325,875 ) Net goodwill at January 1, 2020 2,085,104 364,027 — 2,449,131 Prior period purchase price adjustments (43 ) — — (43 ) Foreign currency translation loss — (23,716 ) — (23,716 ) Balance at June 30, 2020 Goodwill 2,085,061 666,186 — 2,751,247 Accumulated impairment loss — (325,875 ) — (325,875 ) Net goodwill at June 30, 2020 $ 2,085,061 $ 340,311 $ — $ 2,425,372 June 30, 2020 December 31, 2019 Assets (2): U.S. Facilities $ 4,102,085 $ 4,037,968 U.K. Facilities 2,436,753 2,610,357 Corporate and Other 294,390 230,817 $ 6,833,228 $ 6,879,142 (1) Segment EBITDA is defined as income before provision for income taxes, equity-based compensation expense, debt extinguishment costs, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. (2) Assets include property and equipment for the U.S. Facilities of $1.5 billion, U.K. Facilities of $1.6 billion and corporate and other of $48.2 million at June 30, 2020. Assets include property and equipment for the U.S. Facilities of $1.4 billion, U.K. Facilities of $1.7 billion and corporate and other of $50.9 million at December 31, 2019.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Accumulated Other Comprehensive Loss	20. Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss are as follows (in thousands): Foreign Currency Translation Adjustments Change in Fair Value of Derivative Instruments Pension Plan Total Balance at December 31, 2019 $ (434,633 ) $ 24,958 $ (5,209 ) $ (414,884 ) Foreign currency translation (loss) gain (129,522 ) — 339 (129,183 ) Gain on derivative instruments, net of tax of $16.0 million — 43,188 — 43,188 Balance at June 30, 2020 $ (564,155 ) $ 68,146 $ (4,870 ) $ (500,879 )

Financial Information for the C

Financial Information for the Company and Its Subsidiaries	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Financial Information for the Company and Its Subsidiaries	2 1 . Financial Information for the Company and Its Subsidiaries The Company conducts substantially all of its business through its subsidiaries. The 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes and 5.500% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Summarized financial information is presented below is consistent with the condensed consolidated financial statements of the Company, except transactions between combining entities have been eliminated. Financial information for the combined non-guarantor entities has been excluded. Presented below is condensed financial information for Acadia Healthcare Company, Inc. and the combined wholly-owned subsidiary guarantors at June 30, 2020 and December 31, 2019, and for the six months ended June 30, 2020. Summarized balance sheet information (in thousands): June 30, 2020 December 31, 2019 Current assets $ 475,115 $ 427,315 Property and equipment, net 1,367,513 1,313,830 Goodwill 1,992,302 1,992,344 Total noncurrent assets 3,571,187 3,516,967 Current liabilities 362,313 294,289 Long-term debt 2,856,026 2,877,602 Total noncurrent liabilities 3,093,360 3,162,782 Redeemable noncontrolling interests — — Total equity 590,629 487,211 Summarized operating results information (in thousands): Six Months Ended June 30, 2020 Revenues $ 933,772 Income before income taxes 60,120 Net income 46,143 Net income attributable to Acadia Healthcare Company, Inc. 46,143

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2020
U.S. Facilities [Member]
Schedule of Revenue Attributed to Each Category	The table below presents total U.S. revenue attributed to each category (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Acute inpatient psychiatric facilities $ 224,844 $ 229,128 $ 464,258 $ 445,725 Specialty treatment facilities 192,479 201,269 386,090 394,304 Residential treatment centers 68,845 74,084 139,279 147,308 Outpatient community-based facilities 5,307 5,332 11,065 10,436 Revenue $ 491,475 $ 509,813 $ 1,000,692 $ 997,773
Schedule of Revenue and Percentage Generated by Each Payor Type	The following table presents revenue by payor type and as a percentage of revenue in our U.S. Facilities (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Amount % Amount % Amount % Amount % Commercial $ 140,028 28.5 % $ 146,917 28.8 % $ 283,170 28.3 % $ 286,344 28.7 % Medicare 75,914 15.4 % 73,505 14.4 % 148,185 14.8 % 146,121 14.6 % Medicaid 245,690 50.0 % 255,070 50.0 % 505,734 50.5 % 494,261 49.5 % Self-Pay 22,476 4.6 % 29,624 5.8 % 49,510 5.0 % 61,356 6.2 % Other 7,367 1.5 % 4,697 1.0 % 14,093 1.4 % 9,691 1.0 % Revenue $ 491,475 100.0 % $ 509,813 100.0 % $ 1,000,692 100.0 % $ 997,773 100.0 %
Summary of the Activity in Unearned Revenue	A summary of the activity in unearned revenue in the U.S. Facilities is as follows (in thousands): Balance at December 31, 2019 $ 1,896 Payments received $ 49,332 Revenue recognized (3,366 ) Balance at June 30, 2020 $ 47,862
U.K. Facilities [Member]
Schedule of Revenue Attributed to Each Category	The table below presents total U.K. revenue attributed to each category (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Healthcare facilities $ 137,538 $ 155,553 $ 285,675 $ 307,261 Education and Children’s Services 44,630 46,142 91,296 92,264 Adult Care facilities 76,668 77,854 155,458 152,681 Revenue $ 258,836 $ 279,549 $ 532,429 $ 552,206
Schedule of Revenue and Percentage Generated by Each Payor Type	The following table presents revenue by payor type and as a percentage of revenue in our U.K. Facilities (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Amount % Amount % Amount % Amount % U.K. public funded sources $ 235,685 91.1 % $ 252,332 90.3 % $ 481,821 90.5 % $ 497,745 90.1 % Self-Pay 22,556 8.7 % 26,651 9.5 % 49,471 9.3 % 53,465 9.7 % Other 595 0.2 % 566 0.2 % 1,137 0.2 % 996 0.2 % Revenue $ 258,836 100.0 % $ 279,549 100.0 % $ 532,429 100.0 % $ 552,206 100.0 %
Summary of the Activity in Unearned Revenue	A summary of the activity in unearned revenue in the U.K. Facilities is as follows (in thousands): Balance at December 31, 2019 $ 36,579 Payments received 76,680 Revenue recognized (83,748 ) Foreign currency translation loss (1,947 ) Balance at June 30, 2020 $ 27,564

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2020 and 2019 (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Numerator: Net income attributable to Acadia Healthcare Company, Inc. $ 41,079 $ 48,140 $ 74,542 $ 77,611 Denominator: Weighted average shares outstanding for basic earnings per share 87,872 87,618 87,818 87,562 Effect of dilutive instruments 736 219 410 208 Shares used in computing diluted earnings per common share 88,608 87,837 88,228 87,770 Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders: Basic $ 0.47 $ 0.55 $ 0.85 $ 0.89 Diluted $ 0.46 $ 0.55 $ 0.84 $ 0.88

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Transaction Related Expenses as Incurred	Transaction-related expenses primarily relate to termination, restructuring, U.K. sale, strategic review, management transition and other similar costs. Transaction-related expenses for the three and six months ended June 30, 2020 and 2019 were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Legal, accounting and other acquisition-related costs $ 5,202 $ 420 $ 6,530 $ 1,216 Termination, restructuring, sale and strategic review costs 39 3,330 2,260 5,612 Management transition costs — 1,462 — 2,705 $ 5,241 $ 5,212 $ 8,790 $ 9,533

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consisted of the following at June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Land $ 430,222 $ 448,716 Building and improvements 2,747,858 2,746,111 Equipment 503,569 516,769 Construction in progress 257,707 254,213 3,939,356 3,965,809 Less: accumulated depreciation (778,572 ) (741,775 ) Property and equipment, net $ 3,160,784 $ 3,224,034

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Other Identifiable Intangible Assets and Related Accumulated Amortization	Other identifiable intangible assets and related accumulated amortization consisted of the following at June 30, 2020 and December 31, 2019 (in thousands): Gross Carrying Amount Accumulated Amortization June 30, 2020 December 31, 2019 June 30, 2020 December 31, 2019 Intangible assets subject to amortization: Contract intangible assets $ 2,100 $ 2,100 $ (2,100 ) $ (2,100 ) Non-compete agreements 1,131 1,131 (1,131 ) (1,131 ) 3,231 3,231 (3,231 ) (3,231 ) Intangible assets not subject to amortization: Licenses and accreditations 12,427 12,455 — — Trade names 59,457 60,831 — — Certificates of need 17,163 17,071 — — 89,047 90,357 — — Total $ 92,278 $ 93,588 $ (3,231 ) $ (3,231 )

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of Leases on Condensed Consolidated Balance Sheet	The Company recorded the following at June 30, 2020 and December 31, 2019 on the condensed consolidated balance sheets (in thousands): Right-of-Use Assets Balance Sheet Classification June 30, 2020 December 31, 2019 Finance lease right-of-use assets Property and equipment, net $ 43,119 $ 44,370 Operating lease right-of-use assets Operating lease right-of-use assets 475,262 501,837 Total $ 518,381 $ 546,207 Lease Liabilities Balance Sheet Classification June 30, 2020 December 31, 2019 Current: Finance lease liabilities Other accrued liabilities $ 35,229 $ 6,819 Operating lease liabilities Current portion of operating lease liabilities 30,038 29,140 Noncurrent: Finance lease liabilities Other liabilities 14,156 43,662 Operating lease liabilities Operating lease liabilities 474,218 502,252 Total $ 553,641 $ 581,873
Schedule of Weighted-average Remaining Lease Terms and Discount Rates	Weighted-average remaining lease terms and discount rates were as follows at June 30, 2020 and December 31, 2019: June 30, 2020 December 31, 2019 Weighted-average remaining lease term (in years): Finance 6.6 6.9 Operating 18.8 19.4 Weighted-average discount rate: Finance 6.4 % 6.4 % Operating 6.3 % 6.3 %
Schedule of Lease Cost	The Company recorded the following lease costs for the three and six months ended June 30, 2020 and 2019 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Finance lease costs: Depreciation of leased assets 1,048 1,136 2,185 2,259 Interest of lease liabilities 985 999 1,982 1,996 Total finance lease costs $ 2,033 $ 2,135 $ 4,167 $ 4,255 Operating lease costs 16,339 16,237 32,820 32,766 Variable lease costs 1,560 1,044 2,870 1,930 Short term lease costs 1,171 1,483 2,318 2,930 Other lease costs 1,757 1,655 3,643 3,100 Total rents and leases $ 20,827 $ 20,419 $ 41,651 $ 40,726 Total lease costs $ 22,860 $ 22,554 $ 45,818 $ 44,981
Schedule of Undiscounted Cash Flows for Finance and Operating Leases	Undiscounted cash flows for finance and operating leases recorded on the condensed consolidated balance sheets were as follows at June 30, 2020 (in thousands): Finance Leases Operating Leases For the six months ending December 31, 2020 $ 3,690 $ 30,992 2021 35,839 59,215 2022 2,977 54,032 2023 1,768 49,413 2024 1,087 47,082 Thereafter 25,087 657,618 Total minimum lease payments 70,448 898,352 Less: amount of lease payments representing interest 21,063 394,096 Present value of future minimum lease payments 49,385 504,256 Less: Current portion of lease liabilities 35,229 30,038 Noncurrent lease liabilities $ 14,156 $ 474,218
Schedule of Supplemental Data	Supplemental data for the three and six months ended June 30, 2020 and 2019 was as follows (in thousands): Six Months Ended June 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 31,596 $ 31,212 Operating cash flows for finance leases $ 1,982 $ 1,996 Financing cash flows for finance leases $ 1,768 $ 1,684 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 16,939 $ 10,674 Finance leases $ 1,462 $ 1,774

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Components of Long-Term Debt	Long-term debt consisted of the following (in thousands): June 30, 2020 December 31, 2019 Amended and Restated Senior Credit Facility: Senior Secured Term A Loan $ 332,500 $ 346,750 Senior Secured Term B Loans 1,331,936 1,338,928 Senior Secured Revolving Line of Credit — — 6.125% Senior Notes due 2021 — 150,000 5.125% Senior Notes due 2022 — 300,000 5.625% Senior Notes due 2023 650,000 650,000 6.500% Senior Notes due 2024 390,000 390,000 5.500% Senior Notes due 2028 450,000 — Other long-term debt 4,235 4,821 Less: unamortized debt issuance costs, discount and premium (31,761 ) (31,400 ) 3,126,910 3,149,099 Less: current portion (48,465 ) (43,679 ) Long-term debt $ 3,078,445 $ 3,105,420

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Activity	Stock option activity during 2019 and 2020 was as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Options outstanding at January 1, 2019 1,199,540 $ 44.64 7.26 $ 2,717 Options granted 605,200 28.50 9.21 1,343 Options exercised (55,671 ) 19.05 N/A 658 Options cancelled (389,001 ) 40.84 N/A N/A Options outstanding at December 31, 2019 1,360,068 39.40 7.57 1,650 Options granted 443,200 33.72 9.66 — Options exercised (6,000 ) 28.25 N/A 15 Options cancelled (160,462 ) 40.42 N/A N/A Options outstanding at June 30, 2020 1,636,806 $ 37.80 7.73 $ 361 Options exercisable at December 31, 2019 513,290 $ 48.08 5.88 $ 512 Options exercisable at June 30, 2020 690,781 $ 44.33 6.10 $ 361
Schedule of Stock Options Valuation Assumptions	The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the six months ended June 30, 2020 and year ended December 31, 2019 : June 30, 2020 December 31, 2019 Weighted average grant-date fair value of options $ 12.29 $ 17.59 Risk-free interest rate 1.6 % 2.4 % Expected volatility 39 % 38 % Expected life (in years) 5.0 5.0
Restricted Stock Activity	Restricted stock activity during 2019 and 2020 was as follows: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2019 805,057 $ 42.40 Granted 700,937 28.77 Cancelled (389,684 ) 33.50 Vested (311,174 ) 44.23 Unvested at December 31, 2019 805,136 $ 34.14 Granted 557,269 25.27 Cancelled (82,608 ) 35.30 Vested (216,474 ) 37.24 Unvested at June 30, 2020 1,063,323 $ 28.77
Restricted Stock Unit Activity	Restricted stock unit activity during 2019 and 2020 was as follows: Number of Units Weighted Average Grant-Date Fair Value Unvested at January 1, 2019 484,111 $ 44.52 Granted 234,408 34.54 Cancelled (271,162 ) 45.17 Vested — — Unvested at December 31, 2019 447,357 $ 38.89 Granted 583,680 10.60 Cancelled (10,123 ) 42.09 Vested (12,691 ) 42.09 Unvested at June 30, 2020 1,008,223 $ 22.44

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities	The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 5.500% Senior Notes, other long-term debt and derivative instruments at June 30, 2020 and December 31, 2019 were as follows (in thousands): Carrying Amount Fair Value June 30, 2020 December 31, 2019 June 30, 2020 December 31, 2019 Amended and Restated Senior Credit Facility $ 1,649,288 $ 1,668,062 $ 1,649,288 $ 1,668,062 6.125% Senior Notes due 2021 $ — $ 149,254 $ — $ 149,441 5.125% Senior Notes due 2022 $ — $ 297,761 $ — $ 299,994 5.625% Senior Notes due 2023 $ 645,546 $ 644,771 $ 652,001 $ 655,249 6.500% Senior Notes due 2024 $ 385,023 $ 384,430 $ 385,023 $ 398,366 5.500% Senior Notes due 2028 $ 442,818 $ — $ 454,442 $ — Other long-term debt $ 4,235 $ 4,821 $ 4,235 $ 4,821 Derivative instrument liabilities $ (8,683 ) $ (68,915 ) $ (8,683 ) $ (68,915 )

Noncontrolling Interests (Table

Noncontrolling Interests (Tables)	6 Months Ended
	Jun. 30, 2020
Noncontrolling Interest [Abstract]
Summary of Redeemable Noncontrolling Interests	The components of redeemable noncontrolling interests are as follows (in thousands): Balance at December 31, 2019 $ 33,151 Net income attributable to noncontrolling interests 1,239 Dividend payments to noncontrolling interests (451 ) Balance at June 30, 2020 $ 33,939

Other Current Assets (Tables)

Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Other Current Assets	Other current assets consisted of the following (in thousands): June 30, 2020 December 31, 2019 Prepaid expenses $ 20,010 $ 23,708 Other receivables 13,970 16,097 Income taxes receivable 11,437 5,579 Workers’ compensation deposits – current portion 10,000 10,000 Cost report receivable 9,716 13,723 Inventory 4,712 4,759 Insurance receivable – current portion 1,844 3,030 Other 1,806 1,348 Other current assets $ 73,495 $ 78,244

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Other Liabilities Disclosure [Abstract]
Summary of Other Accrued Liabilities	Other accrued liabilities consisted of the following (in thousands): June 30, 2020 December 31, 2019 Unearned revenue $ 75,426 $ 38,475 Accrued expenses 52,977 50,614 Finance lease liabilities 35,229 6,819 Accrued interest 23,228 33,323 Accrued property taxes 6,377 4,755 Income taxes payable 6,196 — Insurance liability – current portion 4,731 4,731 Other 5,959 2,443 Other accrued liabilities $ 210,123 $ 141,160

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2020
Summary of Reconciliation of Segment EBITDA to Income before Income Taxes	The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income before income taxes (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Revenue: U.S. Facilities $ 491,475 $ 509,813 $ 1,000,692 $ 997,773 U.K. Facilities 258,836 279,549 532,429 552,206 Corporate and Other — — — — $ 750,311 $ 789,362 $ 1,533,121 $ 1,549,979 Segment EBITDA (1): U.S. Facilities $ 134,881 $ 135,396 $ 254,955 $ 254,404 U.K. Facilities 31,639 45,835 67,807 85,891 Corporate and Other (22,099 ) (22,345 ) (45,492 ) (45,406 ) $ 144,421 $ 158,886 $ 277,270 $ 294,889 Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Segment EBITDA (1) $ 144,421 $ 158,886 $ 277,270 $ 294,889 Less: Equity-based compensation expense (5,808 ) (4,182 ) (10,787 ) (10,283 ) Transaction-related expenses (5,241 ) (5,212 ) (8,790 ) (9,533 ) Debt extinguishment costs (3,271 ) — (3,271 ) — Interest expense, net (38,726 ) (48,610 ) (81,511 ) (96,740 ) Depreciation and amortization (41,445 ) (41,077 ) (83,125 ) (81,657 ) Income before income taxes $ 49,930 $ 59,805 $ 89,786 $ 96,676
Summary of Assets by Operating Segment	June 30, 2020 December 31, 2019 Assets (2): U.S. Facilities $ 4,102,085 $ 4,037,968 U.K. Facilities 2,436,753 2,610,357 Corporate and Other 294,390 230,817 $ 6,833,228 $ 6,879,142 (1) Segment EBITDA is defined as income before provision for income taxes, equity-based compensation expense, debt extinguishment costs, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. (2) Assets include property and equipment for the U.S. Facilities of $1.5 billion, U.K. Facilities of $1.6 billion and corporate and other of $48.2 million at June 30, 2020. Assets include property and equipment for the U.S. Facilities of $1.4 billion, U.K. Facilities of $1.7 billion and corporate and other of $50.9 million at December 31, 2019.
Goodwill [Member]
Summary of Assets by Operating Segment	U.S. Facilities U.K. Facilities Corporate and Other Consolidated Goodwill: Balance at January 1, 2020 Goodwill $ 2,085,104 $ 689,902 $ — $ 2,775,006 Accumulated impairment loss — (325,875 ) — (325,875 ) Net goodwill at January 1, 2020 2,085,104 364,027 — 2,449,131 Prior period purchase price adjustments (43 ) — — (43 ) Foreign currency translation loss — (23,716 ) — (23,716 ) Balance at June 30, 2020 Goodwill 2,085,061 666,186 — 2,751,247 Accumulated impairment loss — (325,875 ) — (325,875 ) Net goodwill at June 30, 2020 $ 2,085,061 $ 340,311 $ — $ 2,425,372

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss are as follows (in thousands): Foreign Currency Translation Adjustments Change in Fair Value of Derivative Instruments Pension Plan Total Balance at December 31, 2019 $ (434,633 ) $ 24,958 $ (5,209 ) $ (414,884 ) Foreign currency translation (loss) gain (129,522 ) — 339 (129,183 ) Gain on derivative instruments, net of tax of $16.0 million — 43,188 — 43,188 Balance at June 30, 2020 $ (564,155 ) $ 68,146 $ (4,870 ) $ (500,879 )

Financial Information for the_2

Financial Information for the Company and Its Subsidiaries (Tables)	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summarized Balance Sheet	Summarized balance sheet information (in thousands): June 30, 2020 December 31, 2019 Current assets $ 475,115 $ 427,315 Property and equipment, net 1,367,513 1,313,830 Goodwill 1,992,302 1,992,344 Total noncurrent assets 3,571,187 3,516,967 Current liabilities 362,313 294,289 Long-term debt 2,856,026 2,877,602 Total noncurrent liabilities 3,093,360 3,162,782 Redeemable noncontrolling interests — — Total equity 590,629 487,211
Summarized Statements of Income (Loss)	Summarized operating results information (in thousands): Six Months Ended June 30, 2020 Revenues $ 933,772 Income before income taxes 60,120 Net income 46,143 Net income attributable to Acadia Healthcare Company, Inc. 46,143

Description of Business and B_2

Description of Business and Basis of Presentation - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2020FacilityBedState
Accounting Policies [Abstract]
Number of facilities | Facility	589
Number of beds | Bed	18,200
Number of operating states | State	40

The CARES Act - Additional Info

The CARES Act - Additional Information (Detail) - CARES Act [Member] - USD ($) $ in Millions	Apr. 24, 2020	Jun. 30, 2020
CARES Act [Line Items]
Offer of eligible relief amount		$ 100,000
Additional offer of eligible relief amount	$ 75,000
Income related to funds received under CARES Act		$ 18.1
Medicare [Member]
CARES Act [Line Items]
Percentage of increase in medicare reimbursement rate		2.00%
Public Health and Social Services Emergency Fund [Member] | Medicare [Member]
CARES Act [Line Items]
Receipt of CARES Act of 2020 aid amount		$ 20
CMS’ Accelerated and Advance Payment Program [Member] | Medicare [Member]
CARES Act [Line Items]
Amount of advance payment received		$ 45

Revenue - Schedule of U.S. Reve

Revenue - Schedule of U.S. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 750,311	$ 789,362	$ 1,533,121	$ 1,549,979
U.S. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	491,475	509,813	1,000,692	997,773
U.S. Facilities [Member] | Acute Inpatient Psychiatric Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	224,844	229,128	464,258	445,725
U.S. Facilities [Member] | Specialty Treatment Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	192,479	201,269	386,090	394,304
U.S. Facilities [Member] | Residential Treatment Centers [Member]
Disaggregation of Revenue [Line Items]
Revenue	68,845	74,084	139,279	147,308
U.S. Facilities [Member] | Outpatient Community-Based Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 5,307	$ 5,332	$ 11,065	$ 10,436

Revenue - Schedule of U.S. Re_2

Revenue - Schedule of U.S. Revenue and Percentage Generated by Each Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 750,311	$ 789,362	$ 1,533,121	$ 1,549,979
U.S. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 491,475	$ 509,813	$ 1,000,692	$ 997,773
Revenue, Percentage	100.00%	100.00%	100.00%	100.00%
U.S. Facilities [Member] | Commercial [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 140,028	$ 146,917	$ 283,170	$ 286,344
Revenue, Percentage	28.50%	28.80%	28.30%	28.70%
U.S. Facilities [Member] | Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 75,914	$ 73,505	$ 148,185	$ 146,121
Revenue, Percentage	15.40%	14.40%	14.80%	14.60%
U.S. Facilities [Member] | Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 245,690	$ 255,070	$ 505,734	$ 494,261
Revenue, Percentage	50.00%	50.00%	50.50%	49.50%
U.S. Facilities [Member] | Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 22,476	$ 29,624	$ 49,510	$ 61,356
Revenue, Percentage	4.60%	5.80%	5.00%	6.20%
U.S. Facilities [Member] | Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 7,367	$ 4,697	$ 14,093	$ 9,691
Revenue, Percentage	1.50%	1.00%	1.40%	1.00%

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - CARES Act [Member] - CMS’ Accelerated and Advance Payment Program [Member] - Medicare [Member] - USD ($) $ in Millions	1 Months Ended	4 Months Ended
	Apr. 30, 2020	Nov. 30, 2020
Disaggregation of Revenue [Line Items]
Amount of advance payment received	$ 45
Scenario Forecast [Member]
Disaggregation of Revenue [Line Items]
Repayment of advance amount		$ 45

Revenue - Summary of the Activi

Revenue - Summary of the Activity in Unearned Revenue in U.S. Facilities (Detail) - U.S. Facilities [Member] - Unearned Revenue [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Disaggregation of Revenue [Line Items]
Beginning Balance	$ 1,896
Payments received	49,332
Revenue recognized	(3,366)
Ending Balance	$ 47,862

Revenue - Schedule of U.K. Reve

Revenue - Schedule of U.K. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 750,311	$ 789,362	$ 1,533,121	$ 1,549,979
U.K. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	258,836	279,549	532,429	552,206
U.K. Facilities [Member] | Health Care Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	137,538	155,553	285,675	307,261
U.K. Facilities [Member] | Education and Children's Services [Member]
Disaggregation of Revenue [Line Items]
Revenue	44,630	46,142	91,296	92,264
U.K. Facilities [Member] | Adult Care Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 76,668	$ 77,854	$ 155,458	$ 152,681

Revenue - Schedule of U.K. Re_2

Revenue - Schedule of U.K. Revenue and Percentage Generated by Each Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 750,311	$ 789,362	$ 1,533,121	$ 1,549,979
U.K. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 258,836	$ 279,549	$ 532,429	$ 552,206
Revenue, Percentage	100.00%	100.00%	100.00%	100.00%
U.K. Facilities [Member] | U.K. Public Funded Sources [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 235,685	$ 252,332	$ 481,821	$ 497,745
Revenue, Percentage	91.10%	90.30%	90.50%	90.10%
U.K. Facilities [Member] | Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 22,556	$ 26,651	$ 49,471	$ 53,465
Revenue, Percentage	8.70%	9.50%	9.30%	9.70%
U.K. Facilities [Member] | Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 595	$ 566	$ 1,137	$ 996
Revenue, Percentage	0.20%	0.20%	0.20%	0.20%

Revenue - Summary of the Acti_2

Revenue - Summary of the Activity in Unearned Revenue in U.K. Facilities (Detail) - U.K. Facilities [Member] - Unearned Revenue [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Disaggregation of Revenue [Line Items]
Beginning Balance	$ 36,579
Payments received	76,680
Revenue recognized	(83,748)
Foreign currency translation loss	(1,947)
Ending Balance	$ 27,564

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Numerator:
Net income attributable to Acadia Healthcare Company, Inc.	$ 41,079	$ 33,463	$ (11,254)	$ 42,566	$ 48,140	$ 29,471	$ 74,542	$ 77,611
Denominator:
Weighted average shares outstanding for basic earnings per share	87,872				87,618		87,818	87,562
Effect of dilutive instruments	736				219		410	208
Shares used in computing diluted earnings per common share	88,608				87,837		88,228	87,770
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ 0.47				$ 0.55		$ 0.85	$ 0.89
Diluted	$ 0.46				$ 0.55		$ 0.84	$ 0.88

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	2.4	1.9	2.2	2.4

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) $ in Millions	Apr. 01, 2019USD ($)Bed	Feb. 15, 2019USD ($)BedCenter	Jun. 30, 2020Bed
Business Acquisition [Line Items]
Number of beds | Bed			18,200
Bradford [Member]
Business Acquisition [Line Items]
Number of beds | Bed	46
Business acquisition cash consideration | $	$ 4.5
Whittier Pavilion [Member] | Massachusetts [Member]
Business Acquisition [Line Items]
Number of beds | Bed		71
Business acquisition cash consideration | $		$ 17.9
Mission Treatment [Member] | California, Nevada, Arizona and Oklahoma [Member]
Business Acquisition [Line Items]
Business acquisition cash consideration | $		$ 22.5
Number of comprehensive treatment centers operates | Center		9

Acquisitions - Transaction Rela

Acquisitions - Transaction Related Expenses as Incurred (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Business Combinations [Abstract]
Legal, accounting and other acquisition-related costs	$ 5,202	$ 420	$ 6,530	$ 1,216
Termination, restructuring, sale and strategic review costs	39	3,330	2,260	5,612
Management transition costs		1,462		2,705
Transaction-related expenses	$ 5,241	$ 5,212	$ 8,790	$ 9,533

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 3,939,356	$ 3,965,809
Less: accumulated depreciation	(778,572)	(741,775)
Property and equipment, net	3,160,784	3,224,034
Land [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	430,222	448,716
Building and Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,747,858	2,746,111
Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	503,569	516,769
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 257,707	$ 254,213

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Other Assets [Member]
Property Plant And Equipment [Line Items]
Assets held for sale	$ 28.6	$ 31.1

Other Intangible Assets - Other

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	$ 3,231	$ 3,231
Intangible assets not subject to amortization, Gross Carrying Amount	89,047	90,357
Total	92,278	93,588
Intangible assets subject to amortization, Accumulated Amortization	(3,231)	(3,231)
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Total	(3,231)	(3,231)
Contract Intangible Assets [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	2,100	2,100
Intangible assets subject to amortization, Accumulated Amortization	(2,100)	(2,100)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,131	1,131
Intangible assets subject to amortization, Accumulated Amortization	(1,131)	(1,131)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	12,427	12,455
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	59,457	60,831
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	17,163	17,071
Intangible assets not subject to amortization, Accumulated Amortization	$ 0	$ 0

Leases - Additional Information

Leases - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2020
Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	5 years
Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	30 years
Copiers and Equipment [Member] | Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	1 year
Copiers and Equipment [Member] | Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	3 years

Leases - Schedule of Leases on

Leases - Schedule of Leases on Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	$ 475,262	$ 501,837
Total	518,381	546,207
Finance lease liabilities	35,229	6,819
Operating lease liabilities	30,038	29,140
Finance lease liabilities	14,156
Operating lease liabilities	474,218	502,252
Total	553,641	581,873
Property and Equipment, Net [Member]
Lessee Lease Description [Line Items]
Finance lease right-of-use assets	43,119	44,370
Operating Lease Right-of-use Assets [Member]
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	475,262	501,837
Other Accrued Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	35,229	6,819
Current Portion of Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	30,038	29,140
Other Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	14,156	43,662
Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	$ 474,218	$ 502,252

Leases - Schedule of Weighted-a

Leases - Schedule of Weighted-average Remaining Lease Terms and Discount Rates (Detail)	Jun. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Finance lease, weighted average remaining lease term (years)	6 years 7 months 6 days	6 years 10 months 24 days
Operating lease, weighted average remaining term (years)	18 years 9 months 18 days	19 years 4 months 24 days
Finance lease, weighted average discount rate percent	6.40%	6.40%
Operating lease, weighted average discount rate percent	6.30%	6.30%

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Finance lease costs:
Depreciation of leased assets	$ 1,048	$ 1,136	$ 2,185	$ 2,259
Interest of lease liabilities	985	999	1,982	1,996
Total finance lease costs	2,033	2,135	4,167	4,255
Operating lease costs	16,339	16,237	32,820	32,766
Variable lease costs	1,560	1,044	2,870	1,930
Short term lease costs	1,171	1,483	2,318	2,930
Other lease costs	1,757	1,655	3,643	3,100
Total rents and leases	20,827	20,419	41,651	40,726
Total lease costs	$ 22,860	$ 22,554	$ 45,818	$ 44,981

Leases - Schedule of Undiscount

Leases - Schedule of Undiscounted Cash Flows for Finance and Operating Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Finance Leases
For the six months ending December 31, 2020	$ 3,690
2021	35,839
2022	2,977
2023	1,768
2024	1,087
Thereafter	25,087
Total minimum lease payments	70,448
Less: amount of lease payments representing interest	21,063
Present value of future minimum lease payments	49,385
Less: Current portion of lease liabilities	35,229	$ 6,819
Noncurrent lease liabilities	14,156
Operating Leases
For the six months ending December 31, 2020	30,992
2021	59,215
2022	54,032
2023	49,413
2024	47,082
Thereafter	657,618
Total minimum lease payments	898,352
Less: amount of lease payments representing interest	394,096
Present value of future minimum lease payments	504,256
Current portion of operating lease liabilities	30,038	29,140
Operating lease liabilities	$ 474,218	$ 502,252

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Data (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 31,596	$ 31,212
Operating cash flows for finance leases	1,982	1,996
Financing cash flows for finance leases	1,768	1,684
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	16,939	10,674
Finance leases	$ 1,462	$ 1,774

Long-Term Debt - Components of

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Sep. 21, 2015
Debt Instrument [Line Items]
Other long-term debt	$ 4,235	$ 4,821
Less: unamortized debt issuance costs, discount and premium	(31,761)	(31,400)
Long-term debt	3,126,910	3,149,099
Less: current portion	(48,465)	(43,679)
Long-term debt	3,078,445	3,105,420
Amended and Restated Senior Credit Facility [Member] | Senior Secured Term A Loan [Member]
Debt Instrument [Line Items]
Senior Secured	332,500	346,750
Amended and Restated Senior Credit Facility [Member] | Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Senior Secured	1,331,936	1,338,928
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Senior Notes		150,000
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Senior Notes		300,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes	650,000	650,000	$ 650,000
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Senior Notes	390,000	$ 390,000
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Senior Notes	$ 450,000

Long-Term Debt - Components o_2

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Jun. 24, 2020	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%						6.125%
Senior notes maturity year	2021	2021
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%					5.125%
Senior notes maturity year	2022	2022
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%			5.625%	5.625%
Senior notes maturity year	2023	2023
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%		6.50%
Senior notes maturity year	2024	2024
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.50%	5.50%	5.50%
Senior notes maturity year	2028	2028

Long-Term Debt (Amended and Res

Long-Term Debt (Amended and Restated Senior Credit Facility) - Additional Information (Detail) - USD ($) $ in Thousands

Apr. 21, 2020

Feb. 27, 2019

Feb. 06, 2019

Dec. 15, 2015

Dec. 31, 2012

Apr. 01, 2011

May 31, 2020

Apr. 30, 2020

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Jun. 30, 2020

Jun. 30, 2019

Dec. 31, 2017

Dec. 15, 2014

Debt Instrument [Line Items]

Borrowings on revolving credit facility

$ 100,000

$ 76,573

Consolidated funded debt, unrestricted and unencumbered cash to consolidated EBITDA

$ 50,000

Eurodollar [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.50%

Base Rate Loans [Member]

Debt Instrument [Line Items]

Interest on borrowings

1.50%

Tranche B-3 Facility [Member] | Eurodollar [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.50%

Basis spread on variable rate

1.00%

Tranche B-3 Facility [Member] | Base Rate Loans [Member]

Debt Instrument [Line Items]

Interest on borrowings

1.50%

Basis spread on variable rate

0.50%

Tranche B-3 Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.50%

Amended and Restated Senior Credit Facility [Member]

Debt Instrument [Line Items]

Date entered into an agreement

Dec. 31, 2012

Apr. 1, 2011

Amount available under revolving line of credit

$ 485,600

Borrowings on revolving credit facility

$ 100,000

Repayment of revolving credit facility

$ 100,000

Debt instrument maturity date

Nov. 30, 2021

Feb. 11, 2022

Term loan repayments

$ 1,200

Amended and Restated Senior Credit Facility [Member] | Eurodollar [Member]

Debt Instrument [Line Items]

Basis spread on variable rate

1.00%

Amended and Restated Senior Credit Facility [Member] | Base Rate Loans [Member]

Debt Instrument [Line Items]

Basis spread on variable rate

0.50%

Amended and Restated Senior Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.50%

Amended and Restated Senior Credit Facility [Member] | Tranche B-3 Facility [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 447,300

Amended and Restated Senior Credit Facility [Member] | Tranche B-4 Facilities [Member]

Debt Instrument [Line Items]

Debt instrument maturity date

Feb. 16, 2023

Term loan repayments

$ 854,400

Amended and Restated Senior Credit Facility [Member] | Tranche B-4 Facilities [Member] | Eurodollar [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.50%

Basis spread on variable rate

1.00%

Amended and Restated Senior Credit Facility [Member] | Tranche B-4 Facilities [Member] | Base Rate Loans [Member]

Debt Instrument [Line Items]

Interest on borrowings

1.50%

Basis spread on variable rate

0.50%

Amended and Restated Senior Credit Facility [Member] | Tranche B-4 Facilities [Member] | London Interbank Offered Rate (LIBOR) [Member]

Debt Instrument [Line Items]

Interest on borrowings

2.50%

Amended and Restated Senior Credit Facility [Member] | September 30, 2020 to December 31, 2020 [Member]

Debt Instrument [Line Items]

Term loan principal repayments

$ 7,100

Term loan repayments

$ 1,200

Amended and Restated Senior Credit Facility [Member] | March 31, 2021 to September 30, 2021 [Member]

Debt Instrument [Line Items]

Term loan principal repayments

$ 9,500

Amended and Restated Senior Credit Facility [Member] | March 31, 2019 to December 31, 2019 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 1,200

Amended and Restated Senior Credit Facility [Member] | September 30, 2015 to December 31, 2015 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 1,200

Amended and Restated Senior Credit Facility [Member] | Standby Letters Of Credit [Member]

Debt Instrument [Line Items]

Standby letters of credit outstanding

$ 14,400

Amended and Restated Senior Credit Facility [Member] | TLB Facility Due on February 16, 2023 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,300

Amended and Restated Senior Credit Facility [Member] | TLB Facility Due on February 16, 2023 [Member] | September 30, 2020 to December 31, 2020 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,300

Amended and Restated Senior Credit Facility [Member] | TLB Facility Due on February 16, 2023 [Member] | March 31, 2019 to December 31, 2019 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,300

Amended and Restated Senior Credit Facility [Member] | TLB Facility Due on February 16, 2023 [Member] | September 30, 2015 to December 31, 2015 [Member]

Debt Instrument [Line Items]

Term loan repayments

$ 2,300

Eleventh Amendment [Member]

Debt Instrument [Line Items]

Date entered into an agreement

Feb. 6, 2019

Twelfth Amendment [Member]

Debt Instrument [Line Items]

Date entered into an agreement

Feb. 27, 2019

Thirteenth Amendment [Member]

Debt Instrument [Line Items]

Date entered into an agreement

Apr. 21, 2020

Long-Term Debt (6.125% Senior N

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($)	Mar. 12, 2013	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issued Senior Notes	$ 150,000,000
Debt instrument interest rate	6.125%	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		payable semi-annually in arrears on March 15 and September 15 of each year

Long-Term Debt (5.125% Senior N

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes Due 2022 [Member] - USD ($)	Jul. 01, 2014	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issued Senior Notes	$ 300,000,000
Debt instrument interest rate	5.125%	5.125%	5.125%
Debt instrument maturity date	Jul. 1, 2022
Interest on the notes		payable semi-annually in arrears on January 1 and July 1 of each year

Long-Term Debt (Redemption of 6

Long-Term Debt (Redemption of 6.125% Senior Notes and 5.125% Senior Notes) - Additional Information (Detail) - USD ($) $ in Millions	Jun. 10, 2020	Jun. 30, 2020	Dec. 31, 2019	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		6.125%	6.125%		6.125%
Debt instrument, redemption date		Jul. 10, 2020
Debt instrument, redemption price percentage of principal amount	100.00%
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		5.125%	5.125%	5.125%
Debt instrument, redemption price percentage of principal amount	100.00%
6.125% Senior Notes Due 2021 and 5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt extinguishment charge	$ 3.3

Long-Term Debt (5.625% Senior N

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Sep. 21, 2015	Feb. 11, 2015
Debt Instrument [Line Items]
Issued Senior Notes			$ 275,000,000	$ 375,000,000
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Senior Notes	$ 650,000,000	$ 650,000,000	$ 650,000,000
Debt instrument maturity date	Feb. 15, 2023
Interest on the notes	payable semi-annually in arrears on February 15 and August 15 of each year

Long-Term Debt (6.500% Senior N

Long-Term Debt (6.500% Senior Notes due 2024) - Additional Information (Detail) - 6.500% Senior Notes Due 2024 [Member] - USD ($)	Feb. 16, 2016	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issued Senior Notes	$ 390,000,000
Debt instrument interest rate	6.50%	6.50%	6.50%
Debt instrument maturity date	Mar. 1, 2024
Interest on the notes		payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016

Long-Term Debt (5.500% Senior N

Long-Term Debt (5.500% Senior Notes due 2028) - Additional Information (Detail) - 5.500% Senior Notes due 2028 [Member] - USD ($) $ in Millions	Jun. 24, 2020	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issued Senior Notes	$ 450
Debt instrument interest rate	5.50%	5.50%	5.50%
Debt instrument maturity date	Jul. 1, 2028
Interest on the notes		payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021

Equity-Based Compensation - Add

Equity-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	8,200,000		8,200,000
Annual increments in employee grants			25.00%
Equity incentive plan available for future grant	1,064,029		1,064,029
Stock options, contractual term			10 years
Equity-based compensation expense	$ 5,808,000	$ 4,182,000	$ 10,787,000	$ 10,283,000
Unrecognized compensation expense related to unvested options			$ 46,100,000
Vesting period			1 year 4 months 24 days
Warrant outstanding	0		$ 0
Deferred income tax benefit			22,045,000	(205,000)
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 1,500,000	$ 1,100,000	$ 2,900,000	$ 2,800,000
Restricted Stock Award [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Restricted Stock Award [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Restricted Stock Units [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			2 years
Number of shares issuable at the end of the vesting period, percentage			0.00%
Restricted Stock Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Number of shares issuable at the end of the vesting period, percentage			200.00%

Equity-Based Compensation - Sto

Equity-Based Compensation - Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, Beginning balance | shares	1,360,068	1,199,540
Options granted | shares	443,200	605,200
Options exercised | shares	(6,000)	(55,671)
Options cancelled | shares	(160,462)	(389,001)
Options outstanding, Ending balance | shares	1,636,806	1,360,068	1,199,540
Options exercisable, Ending balance | shares	690,781	513,290
Options outstanding, Weighted Average Exercise Price, Beginning balance | $ / shares	$ 39.40	$ 44.64
Options granted, Weighted Average Exercise Price | $ / shares	33.72	28.50
Options exercised, Weighted Average Exercise Price | $ / shares	28.25	19.05
Options cancelled, Weighted Average Exercise Price | $ / shares	40.42	40.84
Options outstanding, Weighted Average Exercise Price, Ending balance | $ / shares	37.80	39.40	$ 44.64
Options exercisable, Weighted Average Exercise Price, Ending balance | $ / shares	$ 44.33	$ 48.08
Options outstanding, Weighted Average Remaining Contractual Term	7 years 8 months 23 days	7 years 6 months 25 days	7 years 3 months 3 days
Options granted, Weighted Average Remaining Contractual Term	9 years 7 months 28 days	9 years 2 months 15 days
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	6 years 1 month 6 days	5 years 10 months 17 days
Options outstanding, Aggregate Intrinsic Value | $	$ 361	$ 1,650	$ 2,717
Options granted, Aggregate Intrinsic Value | $		1,343
Options exercised, Aggregate Intrinsic Value | $	15	658
Options exercisable, Aggregate Intrinsic Value, Ending balance | $	$ 361	$ 512

Equity-Based Compensation - Sch

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options	$ 12.29	$ 17.59
Risk-free interest rate	1.60%	2.40%
Expected volatility	39.00%	38.00%
Expected life (in years)	5 years	5 years

Equity-Based Compensation - Res

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	805,136	805,057
Granted, Number of Shares	557,269	700,937
Cancelled, Number of Shares	(82,608)	(389,684)
Vested, Number of Shares	(216,474)	(311,174)
Unvested, Number of Shares/Units, Ending balance	1,063,323	805,136
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 34.14	$ 42.40
Granted, Weighted Average Grant-Date Fair Value	25.27	28.77
Cancelled, Weighted Average Grant-Date Fair Value	35.30	33.50
Vested, Weighted Average Grant-Date Fair Value	37.24	44.23
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 28.77	$ 34.14

Equity-Based Compensation - R_2

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	447,357	484,111
Granted, Number of Units	583,680	234,408
Cancelled, Number of Units	(10,123)	(271,162)
Vested, Number of Units	(12,691)
Unvested, Number of Shares/Units, Ending balance	1,008,223	447,357
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 38.89	$ 44.52
Granted, Weighted Average Grant-Date Fair Value	10.60	34.54
Cancelled, Weighted Average Grant-Date Fair Value	42.09	45.17
Vested, Weighted Average Grant-Date Fair Value	42.09
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 22.44	$ 38.89

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Effective tax rates	16.50%	19.40%	15.60%	19.60%

Derivatives - Additional Inform

Derivatives - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2019USD ($)	Aug. 31, 2019GBP (£)	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)	Aug. 31, 2019GBP (£)	May 31, 2016USD ($)	May 31, 2016GBP (£)
Derivative [Line Items]
Cross currency swap liabilities			$ (8,700,000)	$ (68,900,000)
Cross Currency Swap Assets [Member]
Derivative [Line Items]
Notional amount	$ 650,000,000				£ 538,100,000	$ 650,000,000	£ 449,300,000
Terminated cross currency swap derivatives	105,000,000
Cross currency swap agreement cash flow due to interest payment	$ 35,800,000	£ 25,400,000

Fair Value Measurements - Carry

Fair Value Measurements - Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	$ 4,235	$ 4,821
Carrying Amount [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	4,235	4,821
Derivative instrument liabilities	(8,683)	(68,915)
Carrying Amount [Member] | Amended and Restated Senior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Secured	1,649,288	1,668,062
Carrying Amount [Member] | 6.125% Senior Notes Due 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		149,254
Carrying Amount [Member] | 5.125% Senior Notes Due 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		297,761
Carrying Amount [Member] | 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	645,546	644,771
Carrying Amount [Member] | 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	385,023	384,430
Carrying Amount [Member] | 5.500% Senior Notes due 2028 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	442,818
Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	4,235	4,821
Derivative instrument liabilities	(8,683)	(68,915)
Fair Value [Member] | Amended and Restated Senior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,649,288	1,668,062
Fair Value [Member] | 6.125% Senior Notes Due 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		149,441
Fair Value [Member] | 5.125% Senior Notes Due 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		299,994
Fair Value [Member] | 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	652,001	655,249
Fair Value [Member] | 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	385,023	$ 398,366
Fair Value [Member] | 5.500% Senior Notes due 2028 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	$ 454,442

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	Jun. 30, 2020	Dec. 31, 2019	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.50%	5.50%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Loss Contingencies [Line Items]
Maximum professional liability aggregate policy limit		$ 75,000,000
Transaction-related expenses	$ 4,000,000
Maximum [Member]
Loss Contingencies [Line Items]
Maximum self insured professional liability limit per claim		3,000,000
Minimum [Member]
Loss Contingencies [Line Items]
Maximum professional liability retention limit		$ 3,000,000

Noncontrolling Interests - Addi

Noncontrolling Interests - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2020Facility
Noncontrolling Interest [Line Items]
Number of facilities operated by non-wholly owned subsidiaries	5
Non-Wholly Owned Subsidiaries [Member] | Minimum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	60.00%
Non-Wholly Owned Subsidiaries [Member] | Maximum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	86.00%

Noncontrolling Interests - Summ

Noncontrolling Interests - Summary of Redeemable Noncontrolling Interests (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Noncontrolling Interest [Abstract]
Balance at December 31, 2019	$ 33,151
Net income attributable to noncontrolling interests	1,239
Dividend payments to noncontrolling interests	(451)
Balance at June 30, 2020	$ 33,939

Other Current Assets - Other Cu

Other Current Assets - Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid expenses	$ 20,010	$ 23,708
Other receivables	13,970	16,097
Income taxes receivable	11,437	5,579
Workers’ compensation deposits – current portion	10,000	10,000
Cost report receivable	9,716	13,723
Inventory	4,712	4,759
Insurance receivable – current portion	1,844	3,030
Other	1,806	1,348
Other current assets	$ 73,495	$ 78,244

Other Accrued Liabilities - Sum

Other Accrued Liabilities - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Accounts Payable And Accrued Liabilities Current [Abstract]
Unearned revenue	$ 75,426	$ 38,475
Accrued expenses	52,977	50,614
Finance lease liabilities	35,229	6,819
Accrued interest	23,228	33,323
Accrued property taxes	6,377	4,755
Income taxes payable	6,196
Insurance liability – current portion	4,731	4,731
Other	5,959	2,443
Other accrued liabilities	$ 210,123	$ 141,160

Segment Information - Additiona

Segment Information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2020FacilityBedState
Segment Reporting Information [Line Items]
Number of facilities | Facility	589
Number of beds | Bed	18,200
Number of operating states | State	40
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities | Facility	231
Number of beds | Bed	9,600
Number of operating states | State	40
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities | Facility	358
Number of beds | Bed	8,600

Segment Information - Summary o

Segment Information - Summary of Reconciliation of Segment EBITDA to Income before Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Revenue	$ 750,311	$ 789,362	$ 1,533,121	$ 1,549,979
Segment EBITDA	144,421	158,886	277,270	294,889
Equity-based compensation expense	(5,808)	(4,182)	(10,787)	(10,283)
Transaction-related expenses	(5,241)	(5,212)	(8,790)	(9,533)
Debt extinguishment costs	(3,271)		(3,271)
Interest expense, net	(38,726)	(48,610)	(81,511)	(96,740)
Depreciation and amortization	(41,445)	(41,077)	(83,125)	(81,657)
Income before income taxes	49,930	59,805	89,786	96,676
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	491,475	509,813	1,000,692	997,773
U.S. Facilities [Member] | Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue	491,475	509,813	1,000,692	997,773
Segment EBITDA	134,881	135,396	254,955	254,404
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	258,836	279,549	532,429	552,206
U.K. Facilities [Member] | Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue	258,836	279,549	532,429	552,206
Segment EBITDA	31,639	45,835	67,807	85,891
Corporate and Other [Member] | Corporate Reconciling Items and Eliminations [Member]
Segment Reporting Information [Line Items]
Segment EBITDA	$ (22,099)	$ (22,345)	$ (45,492)	$ (45,406)

Segment Information - Summary_2

Segment Information - Summary of Financial Information by Operating Segment, Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Goodwill:
Goodwill	$ 2,775,006
Accumulated impairment loss	(325,875)
Net goodwill, beginning balance	2,449,131
Prior period purchase price adjustments	(43)
Foreign currency translation loss	(23,716)
Goodwill	2,751,247
Accumulated impairment loss	(325,875)
Net goodwill, ending balance	2,425,372
U.S. Facilities [Member] | Operating Segment [Member]
Goodwill:
Goodwill	2,085,104
Net goodwill, beginning balance	2,085,104
Prior period purchase price adjustments	(43)
Goodwill	2,085,061
Net goodwill, ending balance	2,085,061
U.K. Facilities [Member] | Operating Segment [Member]
Goodwill:
Goodwill	689,902
Accumulated impairment loss	(325,875)
Net goodwill, beginning balance	364,027
Foreign currency translation loss	(23,716)
Goodwill	666,186
Accumulated impairment loss	(325,875)
Net goodwill, ending balance	$ 340,311

Segment Information - Summary_3

Segment Information - Summary of Financial Information by Operating Segment, Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Assets:
Assets	$ 6,833,228	$ 6,879,142
U.S. Facilities [Member] | Operating Segment [Member]
Assets:
Assets	4,102,085	4,037,968
U.K. Facilities [Member] | Operating Segment [Member]
Assets:
Assets	2,436,753	2,610,357
Corporate and Other [Member] | Corporate Reconciling Items and Eliminations [Member]
Assets:
Assets	$ 294,390	$ 230,817

Segment Information - Summary_4

Segment Information - Summary of Financial Information by Operating Segment, Assets (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 3,160,784	$ 3,224,034
Operating Segment [Member] | U.S. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,500,000	1,400,000
Operating Segment [Member] | U.K. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,600,000	1,700,000
Corporate Reconciling Items and Eliminations [Member] | Corporate and Other [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 48,200	$ 50,900

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 2,464,167	$ 2,403,343	$ 2,505,381	$ 2,333,307
Foreign currency translation (loss) gain	(7,183)	(50,618)	(129,183)	(6,137)
Gain on derivative instruments, net of tax of $16.0 million	(558)	17,587	43,188	8,897
Balance	2,503,338	2,422,346	2,503,338	2,422,346
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(434,633)
Foreign currency translation (loss) gain			(129,522)
Balance	(564,155)		(564,155)
Change in Fair Value of Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			24,958
Gain on derivative instruments, net of tax of $16.0 million			43,188
Balance	68,146		68,146
Pension Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(5,209)
Foreign currency translation (loss) gain			339
Balance	(4,870)		(4,870)
Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(493,138)	(426,586)	(414,884)	(462,377)
Balance	$ (500,879)	$ (459,617)	$ (500,879)	$ (459,617)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Gain on derivative instruments, tax	$ (0.2)	$ 9.2	$ 16	$ 5.7

Financial Information for the_3

Financial Information for the Company and Its Subsidiaries - Additional Information (Detail)	Jun. 30, 2020	Jun. 24, 2020	Dec. 31, 2019	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.125%		6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.125%		5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%		5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.50%		6.50%	6.50%
5.500% Senior Notes due 2028 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.50%	5.50%	5.50%

Financial Information for the_4

Financial Information for the Company and Its Subsidiaries - Summarized Balance Sheet (Detail) - USD ($) $ in Thousands	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Condensed Financial Statements, Captions [Line Items]
Current assets	$ 610,941		$ 542,211
Property and equipment, net	3,160,784		3,224,034
Goodwill	2,425,372		2,449,131
Current liabilities	527,364		463,576
Long-term debt	3,078,445		3,105,420
Redeemable noncontrolling interests	33,939		33,151
Total equity	2,503,338	$ 2,464,167	2,505,381	$ 2,420,691	$ 2,422,346	$ 2,403,343	$ 2,333,307
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Current assets	475,115		427,315
Property and equipment, net	1,367,513		1,313,830
Goodwill	1,992,302		1,992,344
Total noncurrent assets	3,571,187		3,516,967
Current liabilities	362,313		294,289
Long-term debt	2,856,026		2,877,602
Total noncurrent liabilities	3,093,360		3,162,782
Total equity	$ 590,629		$ 487,211

Financial Information for the_5

Financial Information for the Company and Its Subsidiaries - Summarized Statements of Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Condensed Financial Statements, Captions [Line Items]
Revenue	$ 750,311				$ 789,362		$ 1,533,121	$ 1,549,979
Income before income taxes	49,930				59,805		89,786	96,676
Net income	41,714				48,201		75,781	77,712
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ 41,079	$ 33,463	$ (11,254)	$ 42,566	$ 48,140	$ 29,471	74,542	$ 77,611
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue							933,772
Income before income taxes							60,120
Net income							46,143
Net income (loss) attributable to Acadia Healthcare Company, Inc.							$ 46,143